AI-DRIVEN REPRODUCIBILITY AND ANALYTICAL ROBUSTNESS IN SCIENTIFIC DISCOVERY

Anonymous authors
Paper under double-blind review

ABSTRACT

Reproducible and analytically robust research findings are essential to scientific progress, but evaluating these properties typically requires costly manual effort. We investigate whether LLM agents can help automate reproduction and robustness analysis, using a medical case study grounded in the Surveillance, Epidemiology, and End Results (SEER) database, a widely used U.S. cancer registry underlying tens of thousands of published studies. First, we introduce **SEER-Repro**, a benchmark of 20 published SEER-based papers together with the data and resources required to reproduce their findings. Second, we create an AI agent that successfully reproduces 79.1% of 2,190 atomic claims, while providing executable baselines for further analysis. Third, we develop an agentic analysis pipeline to test the robustness of the medical findings by identifying analytical choices underlying each finding, proposing defensible alternatives, and rerunning the analysis to determine whether those choices affect the conclusion. Across published papers in SEER-Repro, our pipeline finds that major effects on principal conclusions are flagged in 5.9% of fully reproduced findings. These results show how LLM agents can support scientific review by reproducing findings, systematically testing their robustness, and directing expert attention toward potentially consequential analytical choices.

1 INTRODUCTION



Figure 1: AI-assisted robustness assessment pipeline to support expert review.

Reproducibility and analytical robustness are the bedrock on which scientific discovery rests. Reproducibility ensures that research findings can be independently verified, while analytical robustness asks whether conclusions remain stable under reasonable alternative choices. Traditionally, meta-analyses and systematic reviews have addressed these challenges through laborious, manual efforts to reproduce experiments or reanalyze data using alternate specifications (Delios et al., 2022; Brodeur et al., 2026). However, the immense cost and expertise required for such metascientific investigations have limited their scalability. Scientific claims also depend on the analytical decisions made by their authors (Simonsohn et al., 2020; Bertran et al., 2026). Recent "many-analyst"

Reviewers: please read the Reviewer Guidelines (iclr.cc/Conferences/2027/ReviewerGuidelines) and the AI Policy for Reviewers (iclr.cc/Conferences/2027/AIPolicyForReviewers). If you used AI to expand, edit, or polish your review, please provide the input text to the LLM. Better still, consider skipping the LLM and submitting your original text: we, and the authors, are much more interested in your unedited thoughts than in what an LLM has to say. AI-assisted or not, you are putting your name and reputation behind your review: LLM-generated falsehoods, hallucinations or misrepresentations are subject to disciplinary action, which may include desk-rejecting all papers you have authored.

studies in psychology and the social sciences show that independent teams addressing the same hypothesis and dataset can reach conflicting conclusions (Silberzahn et al., 2018; Breznau et al., 2022; Botvinik-Nezer et al., 2020). Large language models (LLMs) offer a way to explore this analytical diversity at scale. Importantly, these AI-driven results exhibit notable steerability: shifting the design of the analyst persona or changing the underlying LLM meaningfully alters the distribution of analytic outcomes, even when methodological rigor is maintained throughout (Bertran et al., 2026; Miao et al., 2026).

Does this sensitivity to analytical choices documented in psychological and social sciences extend to medicine, where findings profoundly inform clinical decisions and patient care? Addressing this question is critical, as the validity of medical research underpins clinical decisions that affect countless lives. In this paper, we investigate the potential of AI-driven analysts to enhance both *reproducibility* and *analytical robustness* in scientific discovery, with a particular focus on medical epidemiology using the Surveillance, Epidemiology, and End Results (SEER) database. Maintained by the National Cancer Institute since 1973, the program integrates population-based cancer-registry records on patient demographics, tumor characteristics, treatment, and survival. In its 2024 usage metrics, NCI reports that 17 core registries cover roughly 48% of the U.S. population and collect approximately 950,000 incident cases per year (National Cancer Institute, 2026d; 2025). From 1975 through 2024, approximately 25,000 publications used SEER data in their primary analysis, while more than 126,000 publications referenced SEER data (National Cancer Institute, 2025). This scale provides a large body of realistic, high-impact questions, while differences in data and analytical definitions, such as registry coverage and cohort selection, make faithful reconstruction challenging.

We argue that, before LLMs can be trusted to produce new scientific results, they must first demonstrate the ability to accurately reproduce existing scientific studies and assess their analytical robustness. Motivated by this prerequisite, this paper addresses two key research questions:

First, can we create an AI agent to reproduce published medical epidemiological studies? And if so, what is the reproducibility rate of such papers? We construct **SEER-Repro**, the first benchmark consisting of 20 original recent or highly cited papers published on the SEER data. We develop an AI agent to reproduce the results of each paper by reading the paper and database documentation, writing and executing the code to access and process the SEER data accordingly. Across 2,190 atomic claims, our pipeline reproduced 79.1%, while 3.6% were close and 17.3% were not reproduced. Error analysis identifies unavailable data as the main barrier to reproduction, despite extensive efforts to recover all required data.

Second, can we create an AI agent to evaluate the analytical robustness of findings in SEER-Repro? And if so, how robust are those findings to reasonable alternative analytical choices? We formulate the task of **analytical robustness evaluation** as follows: Given a research report and access to the underlying data, the task is to investigate if there are well-justified analytical choices that can change the conclusions of the report. We refer to such choices as **consequential**. Evaluating analytical robustness is challenging because gold-standard judgments do not exist. We therefore investigate three complementary approaches: (1) asking a coding agent to independently analyze the data and comparing its conclusions with those of the published paper; (2) systematically perturbing individual analytical choices through a structured agentic pipeline; and (3) asking coding agents to assess analytical robustness directly. To rate how strongly alternative analyses could change published conclusions, we adapted GRADE (Guyatt et al., 2008), an established framework for evaluating clinical evidence that rates the importance of outcomes on a nine-point scale, with scores of 7-9 indicating outcomes critical to decision-making.

Our results show that major effects (scores 7–9) are flagged in 5.9% of fully reproduced findings (34 of 579). Expert review of 10 flagged cases found that 9 did not establish a consequential change under a defensible alternative, while 1 required further review. Thus, in contrast to the sensitivity reported for the social science datasets studied by Bertran et al. (2026) and Miao et al. (2026), our findings suggest that the medical papers in SEER-Repro exhibit a high degree of robustness to the analytical alternatives tested—an encouraging sign for the reliability of published medical research.

Overall, our results show how LLM agents can strengthen the scientific process by reproducing findings, systematically testing their robustness, and directing expert attention toward potentially consequential analytical choices.

2 Related Work

2.1 Reproduction and Robustness to Analytical Choice in Scientific Research

Multiverse and specification-curve analyses examine results across defensible analytical specifications, while many-analyst studies demonstrate that independent teams can reach different conclusions from the same data and question (Steegen et al., 2016; Simonsohn et al., 2020; Silberzahn et al., 2018). Related efforts test published findings through reproduction and reanalysis: Delios et al. (2022) extend archival analyses to new observations, and Brodeur et al. (2026) reproduce analyses and conduct robustness checks for 110 economics and political science articles. These studies motivate assessing both whether a finding can be reproduced and whether it survives alternative analytical choices. In this work, we investigate whether an LLM-assisted pipeline can help with this important scientific problem.

Recent work automates robustness exploration with AI agents. Bertran et al. (2026) generate analyses with multiple AI analysts and screen their methodological validity with an AI analysis agent. Miao et al. (2026) sample agent-generated specifications and estimate how often defensible paths produce claims at least as extreme as the reported finding. Such analytical variation can reflect subjective judgments about how to operationalize a research question. We investigate how this problem manifests in medical epidemiology, where choices about cancer cohorts, outcome definitions, and statistical analyses can alter findings relevant to clinical practice and public health.

2.2 Data-Driven Deep Research Benchmarks and Evaluation

Deep-research benchmarks such as DeepResearchBench, ReportBench, and DeepScholar-Bench assess report quality, evidence coverage, and citation grounding (Du et al., 2025; Li et al., 2025; Patel et al., 2025). Data-oriented benchmarks evaluate insight generation and executable scientific workflows, including InsightBench, DiscoveryBench, and ScienceAgentBench (Sahu et al., 2025; Majumder et al., 2025; Chen et al., 2025). BLADE additionally evaluates conceptual variables, transformations, and models across multiple valid analyses (Gu et al., 2024). DataSTORM, Hunt, and DAgent extend this setting to database investigation and report generation (Liu et al., 2026a;b; Xu et al., 2025). Our evaluation asks whether a report's conclusions survive defensible changes to the analytical choices that produced them, using executed alternatives linked to individual findings. This report-level assessment of analytical robustness is not covered by these prior benchmarks and evaluations.

3 Methodology

3.1 Automated Pipeline for Reproducing Published Findings

In this section, we provide an overview of our proposed agent for reproducing published scientific findings. Our process starts with the paper p that we are interested in reproducing:

Extract findings and atomic claims: First, we extract the empirical findings $F_p = \{f_1, \ldots, f_m\}$. These findings represent the core contributions of the paper and underpin the conclusion it draws. We exclude sections of the paper pertaining to related work, background context, or methodology. Each finding f_i is then decomposed into a set of atomic claims $A_i = \{a_{i1}, \ldots, a_{in}\}$. One atomic claim involves one specific numerical or qualitative target while one finding could group multiple atomic claims together. For instance, "Among women with adenoid cystic carcinoma of the breast, the mean age at diagnosis was 63 years, the median was 62 years, and the range was 33–97 years" is a finding, while its individual targets such as "Among women with adenoid cystic carcinoma of the breast, the mean age at diagnosis was 63 years" (and similarly for "median age: 62 years" and "age range: 33–97 years") each become a separate atomic claim.

Reproduce findings: We then ask a coding agent to reproduce each finding f_i using the original paper p, the data used by the paper, and any additional documentation for the data. The agent identifies the relevant data, writes analysis code, and executes it to produce evidence e_i for whether the finding can be validated or not. The evidence e_i includes the output of any analytical code and its results.



Figure 2: AI-driven analytical robustness with 3 complementary methods discussed in Sec 3.2

Grade individual claims: Finally, for each atomic claim and evidence pair (a_{ij}, e_i), a claim verification agent checks the method, extracts the reproduced result, and assesses the quantitative or qualitative agreement with the known target values in a_{ij} to produce a final verdict $v_{ij} \in \{\text{REPRODUCED}, \text{CLOSE}, \text{NOTREPRODUCED}\}$. For numerical targets, we consider a claim reproduced if the relative error is at most 5%, while errors greater than 5% and at most 10% are counted as close. Qualitative claims are deemed either reproduced or not reproduced. The full protocol for grading is presented in Appendix F.

3.2 Analytical Robustness Analysis

The reproduction artifacts, including the exact code derived, then serve as a foundation for analytic robustness evaluation. Our overall approach uses 3 complementary methods illustrated in Figure 2.

3.2.1 Independent Report Generation

Our first method asks whether an independent analysis of the same research question would reach a conclusion that contradicts the original paper (Figure 2 (A)). For each paper p, a coding agent receives a research question specifying the topic and scope derived from p, together with access to relevant data and additional documentation about the data, if available, and is tasked with independently answering the research question. The agent chooses its analytical approach, writes and executes code, and produces a research report r. We then judge whether the conclusions in r contradict those in p. Appendix C documents the report-generation setup and the prompts for all 20 research questions.

3.2.2 Perturbation Agent

Our second method uses the Perturbation Agent illustrated in Figure 2 (B) and Algorithm 1. Appendix D details the implementation of each component, including prompts.

Algorithm 1 Perturbation Agent

Input: Paper p, reproduced findings F_p^{rep}, reproduction evidence E_p, LLM-generated reports r from Sec 3.2.1
Output: A list of outcomes $y_k(v) \in$ `AnalysisOutcome` and an associated 1–9 score for $y_k(v) =$ `DirectChange`

1: $\mathcal{C}_p \leftarrow$ SELECTANALYTICALCHOICES$(p, r, F_p^{\text{rep}}, E_p)$
2: $\mathcal{K}_p \leftarrow$ PROPOSEALTERNATIVES$(p, r, \mathcal{C}_p, E_p)$
3: **for** each choice–alternative comparison $(k, v) \in \mathcal{K}_p$ **do**
4: $\quad e_k(v) \leftarrow$ EXECUTEANALYSES(k, v).
5: $\quad y_k(v) \leftarrow$ ASSESSCONSEQUENCES$(k, v, e_k(v))$.
6: $\quad$ If $y_k(v) =$ `DirectChange`, assign a 1–9 consequentiality score.
7: **end for**
8: **return** comparison outcomes and consequentiality scores.

Eligible findings. For a published paper p, we start from the findings reproduced according to Section 3.1:

$$F_p^{\text{rep}} = \{f_i \in F_p : v_{ij} \text{ is reproduced for every } a_{ij} \in A_i\}. \tag{1}$$

Only fully reproduced findings enter the robustness analysis: their reconstructed results have passed the reproduction criteria in Section 3.1, and their reproduction code provides the baseline for testing alternative analytical choices.

SELECTANALYTICALCHOICES: First, the pipeline identifies analytical choices made in p that contribute to the known outcome for the findings F_p^{rep}, such as cohort definitions, endpoints, or statistical models. Independent reports r generated are used as an additional reference. These choices are then ordered by scientific importance and feasibility to select up to 20 choices which form the final set of choices $\mathcal{C}_p$.

PROPOSEALTERNATIVES: Next, the pipeline establishes how the paper p implements each selected choice in $\mathcal{C}_p$, using the reproduction evidence $E_p = \{e_i\}_{i=1}^m$, where e_i contains the evidence for finding f_i. It then proposes defensible alternatives. The resulting set $\mathcal{K}_p$ contains comparisons (k, v), where each $k \in \mathcal{C}_p$ is a selected analytical choice and v is a proposed alternative setting.

EXECUTEANALYSES: For each comparison (k, v), we run the baseline unchanged and validate it against the available evidence. We then apply the alternative choice while holding the remaining analysis fixed.

ASSESS CONSEQUENCES: Finally, the pipeline assigns each comparison an outcome $y_k(v)$ from the enumerated type

$$\begin{aligned}\texttt{AnalysisOutcome} = \{&\texttt{DirectChange}, \texttt{Qualification},\\ &\texttt{StableUnderTest}, \texttt{Inconclusive},\\ &\texttt{Unavailable}, \texttt{NotTested}\}.\end{aligned} \tag{2}$$

`DirectChange` denotes a change to a stated finding; `Qualification` narrows its scope or evidentiary strength without directly changing its conclusion; and `StableUnderTest` means the completed comparison does not meet the criterion for a consequential change. `Inconclusive` means the evidence cannot support a verdict, `Unavailable` indicates missing required inputs or baseline evidence, and `NotTested` records comparisons excluded before execution.

The outcome label only describes what happens to the tested finding. For `DirectChange` outcomes, we additionally grade the effect on the source's conclusions from 1 to 9, using a scale adapted from GRADE's outcome-importance framework (Guyatt et al., 2008). Scores 1–3 indicate quantitative sensitivity without substantive interpretive change, 4–6 indicate qualifications or changes to secondary findings, and 7–9 indicate major qualification, loss of support, or reversal of a principal conclusion.

3.2.3 DIRECT CODING AGENT ANALYSIS

Our third method asks a coding agent to identify and test consequential analytical choices directly (Figure 2 (C)). For each paper, the agent receives the paper p, the available reproduction evidence E_p, and access to the data and data documentation when available. We then instruct the agent

Table 1: Atomic reproduction outcomes for the 20-paper SEER-Repro benchmark using GPT-5.6 Sol. Appendix Table 8 gives exact outcome counts and percentages; Appendix G lists full paper titles; Appendix Table 9 separates quantitative and qualitative claims.

Paper (shorter name)	Journal (year)	Cit.	Findings	Atomic claims	Reproduced	Close	Not reproduced
Bone sarcoma survival by tumor site (Hu et al., 2021)	Cancers (2021)	37	56	188	187 (99.5%)		
Sex disparities in cancer incidence (Cook et al., 2009)	Cancer Epidemiol. Biomarkers Prev. (2009)	466	36	153	146 (95.4%)		
Inflammatory breast cancer incidence and survival (Hance et al., 2005)	J. Natl. Cancer Inst. (2005)	702	40	131	118 (90.1%)		
Fatal prostate cancer incidence by race (Kelly et al., 2017)	Eur. Urol. (2017)	111	32	64	57 (89.1%)		
Thyroid cancer trends (Davies & Welch, 2014)	JAMA Otolaryngol. Head Neck Surg. (2014)	1,628	33	91	78 (85.7%)		
Age at oropharyngeal cancer diagnosis (Cline et al., 2020)	Cancers (2020)	29	75	154	129 (83.8%)		
Childhood cancer incidence and mortality (Linet et al., 1999)	J. Natl. Cancer Inst. (1999)	438	52	139	115 (82.7%)		
Esophageal adenocarcinoma incidence and mortality (Hur et al., 2013)	Cancer (2013)	510	33	53	43 (81.1%)		
Adenoid cystic carcinoma of the breast (Ghabach et al., 2010)	Breast Cancer Res. (2010)	188	51	128	103 (80.5%)		
Adult diffuse glioma incidence (Li et al., 2018)	Cancer Med. (2018)	72	60	111	89 (80.2%)		
Head and neck mucosal melanoma incidence (Marcus et al., 2012)	J. Skin Cancer (2012)	83	20	54	42 (77.8%)		
Second cancers after young-onset colorectal cancer (He et al., 2018)	Cancer Med. (2018)	43	59	124	95 (76.6%)		
Age disparities in colorectal cancer incidence (Bailey et al., 2015)	JAMA Surg. (2015)	1,102	27	70	52 (74.3%)		
Lung cancer incidence by sex, race, and histology (Meza et al., 2015)	PLOS ONE (2015)	368	36	111	80 (72.1%)		
Intracranial glioma incidence and mortality (Lin et al., 2021)	Front. Oncol. (2021)	116	67	94	66 (70.2%)		
Long-term mortality in young cancer survivors (Moke et al., 2021)	Cancers (2021)	23	62	178	123 (69.1%)		
Esophageal versus gastric cardia adenocarcinoma (El-Serag et al., 2002)	Gut (2002)	266	34	54	36 (66.7%)		
Breast cancer incidence by age and tumor features (Jemal et al., 2007)	Breast Cancer Res. (2007)	352	31	74	46 (62.2%)		
Metastatic cancer incidence and survival (Hudock et al., 2023)	Commun. Med. (2023)	68	51	101	59 (58.4%)		
Cervical cancer incidence by race and histology (Wang et al., 2004)	Cancer (2004)	448	46	118	68 (57.6%)		
Total			**901**	**2,190**	**1,732 (79.1%)**	**78 (3.6%)**	**380 (17.3%)**

to select scientifically defensible alternatives addressing the same research question, validate the baseline analysis, and, where feasible, execute comparisons that vary one choice while holding the remaining analysis fixed (with Prompt 32). It produces a report describing the choices tested, the supporting evidence, and their effects on the source's conclusions. After the analysis, we grade all output choices using the same 1–9 scale as in Section 3.2.2.

4 Experiments

4.1 SEER-Repro Construction Challenges

We apply our pipeline to published SEER findings. Reconstructing these studies presents two challenges:

Historical data availability. Detroit was excluded from the April 2022 release, changing SEER 9, 13, and 18 to SEER 8, 12, and 17 (National Cancer Institute, 2026b). We focus on SEER 9 studies because a retained supplement covers 1975–2018, including Detroit (National Cancer Institute, 2026f). Current releases cannot recover the exact historical SEER 13 and 18 cohorts. Appendix A details remaining limitations.

Table 2: Classification of all 380 non-reproduced atomic claims from 20 papers in SEER-Repro.

Category	Meaning	Claims	%
Data issues	Unavailable data (198 cases) or a data-related explanation such as mismatches attributed to revised records and population denominators (47 cases).	245	64.5
Insufficiently specified analysis	The available paper and documentation do not uniquely specify the target analysis.	41	10.8
Unavailable-software approximations	Method substitutions involving approximations of unavailable software such as NCI Joinpoint.	28	7.4
Agent-side errors	Departures from the reported method or comparison (8), incorrect cohort (10), statistical inference (3), denominator or standardization (2), or an omitted analysis (1).	24	6.3
Suspected evaluation errors	Suspected errors in our claim extraction or grading.	22	5.8
Unresolved cause	The evidence does not identify a sufficiently specific cause of non-reproduction.	20	5.3

Fragmented data and documentation. Epidemiological studies often rely on external population data and relevant manuals. We curate these resources manually through an iterative process with expert input. Missing inputs often become apparent only as individual analyses are reconstructed, and identifying what is missing can itself require tracing the analysis step by step. For example, reproducing an incidence rate requires identifying an appropriate population denominator, locating its source, and checking that its geographic coverage, calendar years, and demographic definitions match the cancer records. Selecting among candidate sources also requires assessing their suitability and consulting the relevant manuals. This process therefore requires manual curation and expert judgment, rather than simply retrieving a known list of files.

We curated four county-population tables, 34 SEER*Explorer tables, and associated documentation on coding, staging, registry mappings, and population methods (Appendix B). On an 11-paper subset, an earlier run without manuals reproduced 72.5% of claims, compared with 78.1% in the updated setting with manuals and SEER*Explorer tables.

4.2 SEER-Repro Benchmark and Reproduction Outcome

We collect the ten most cited eligible papers and ten more recent papers in SEER-Repro. Using GPT-5.6 Sol xhigh via Codex, our reproduction agent reproduces 1,732 of 2,190 atomic claims (79.1%); 78 are close (3.6%) and 380 are not reproduced (17.3%; Table 1). We classify the 380 failures using Prompt 6. Data issues account for 245 (64.5%), insufficiently specified analyses for 41 (10.8%), unavailable-software approximations for 28 (7.4%), and agent-side errors for 24 (6.3%; Table 2).

The benchmark packages 39 data tables and 40 documentation resources (Appendix B), together with the 2,190 atomic claims over 20 papers. Each claim $a_{ij} \in A_i$ links to its paper p, parent finding f_i, verdict v_{ij}, and reproduction evidence e_i, including code and available execution outputs.

4.3 Robustness Analysis of SEER-Repro

4.3.1 Independent Report Generation

For each paper, we independently ask Opus 4.8 max via Claude Code and GPT-5.6 Sol xhigh via Codex to generate a report. GPT-5.6 Sol then compares each of the 40 reports with its corresponding paper for contradictions on their shared research question (Prompt 1). The judge identifies no contradictions in the central conclusions of the 39 comparable reports (19 Sol and 20 Opus). One Sol report analyzes a nonoverlapping study period and is not comparable. It marked 3 Opus reports as containing contradictions in supporting statements, but these do not overturn their central conclusions upon closer scrutiny. These results suggest that independent analyses generally reach central conclusions non-contradictory with the published papers.

4.3.2 Perturbation Agent and Direct Coding Agent Analysis

Table 3: Model-assessed consequential links (scores 7–9): finding counts by paper and analyst.

Paper	Eligible findings	Findings with consequential links							
		Perturbation Agent				Direct coding agent		Found by	
		Sol	Opus	Kimi	GLM	Codex	Claude Code	≥ 1 analyst	≥ 2 analysts
Bone sarcoma survival by tumor site	55	3	–	2	–	–	–	4	1
Sex disparities in cancer incidence	31	–	–	–	–	–	–	–	–
Inflammatory breast cancer incidence and survival	31	–	3	–	–	2	2	4	2
Fatal prostate cancer incidence by race	20	–	–	5	–	–	1	6	–
Thyroid cancer trends	24	–	–	–	–	–	–	–	–
Age at oropharyngeal cancer diagnosis	53	–	–	–	–	–	–	–	–
Childhood cancer incidence and mortality	28	–	–	–	1	–	–	1	–
Esophageal adenocarcinoma incidence and mortality	23	–	–	–	2	–	–	2	–
Adenoid cystic carcinoma of the breast	37	–	–	–	–	1	–	1	–
Adult diffuse glioma incidence	40	–	–	–	–	–	–	–	–
Head and neck mucosal melanoma incidence	12	–	–	–	1	–	–	1	–
Second cancers after young-onset colorectal cancer	44	–	–	–	–	1	2	2	1
Age disparities in colorectal cancer incidence	10	–	–	–	3	–	–	3	–
Lung cancer incidence by sex, race, and histology	13	–	–	–	–	–	–	–	–
Intracranial glioma incidence and mortality	47	–	–	1	–	–	–	1	–
Long-term mortality in young cancer survivors	40	2	3	3	–	2	–	4	2
Esophageal versus gastric cardia adenocarcinoma	15	–	–	–	–	–	–	–	–
Breast cancer incidence by age and tumor features	15	–	2	–	–	–	–	2	–
Metastatic cancer incidence and survival	22	–	1	1	–	1	2	2	1
Cervical cancer incidence by race and histology	19	–	–	1	–	–	–	1	–
Total	**579**	**5**	**9**	**13**	**7**	**7**	**7**	**34**	**7**

We run the Perturbation Agent with GPT-5.6 Sol (OpenAI, 2026), Opus 4.8 (Anthropic, 2026), Kimi K3 (Kimi Team, 2026), and GLM 5.3 (Z.ai, 2026), together with direct coding agent analyses through GPT-5.6 Sol xhigh via Codex and Opus 4.8 max via Claude Code. These correspond to methods B and C in Figure 2. GPT-5.6 Sol then assigned scores of 7–9 to 54 results (Prompt 33). These scores indicate a model-assessed major qualification, loss of support, or reversal of a principal conclusion and help identify shortlisted candidates for expert examination.



Figure 3: GPT-5.6 Sol consequence scores for analyses of published papers; shading marks scores 7–9.

We use GPT-5.6 Sol to link these high-score results back to the original findings in each paper (Prompt 34). A model-assessed consequential link requires reported evidence of a reversal, loss of support, major qualification, or material change to a quantity central to the specific finding. Table 3 shows that 34 of the 579 fully reproduced findings (5.9%) have such a link from at least one analyst, and seven (1.2%) from at least two analysts.

Discussion: As mentioned in Section 3.2, we restrict this analysis to fully reproduced findings. This provides executable baselines whose results passed the reproduction criteria in Section 3.1. The analysts can therefore compare an alternative against a reconstructed result supported by reproduction evidence. We further consider two questions:

Do different analysts complement each other? Results in Table 3 show that most of the affected findings—27 of 34 (79.4%)—are identified by only one analyst. This suggests that different analysts identify largely complementary sets of potentially consequential analytical choices.

Distribution of consequence scores. Among results with a 1–9 grade (Figure 3), scores 7–9 account for 7.5–14.8% of Perturbation Agent comparisons, 19.4% of Codex results, and 17.4% of Claude Code results. Thus, most graded results do not reach the high-consequence range.

Table 4: Three expert-reviewed cases, one per assessment category.

Paper and original conclusion	Alternative analysis and result	Expert assessment
Bone sarcoma survival by tumor site. Sol, Perturbation Agent; score 9. Adjusted cancer-specific mortality did not significantly improve in the 2000s or 2010s relative to the 1990s.	Replace the SEER "Bones and Joints" recode with direct primary-site codes C40.0–C41.9. The implementation added 3,974 records; both period comparisons then showed significant improvements.	**Likely less defensible alternative.** The added records change the disease population, and closer examination of the database contents and manuals suggests that the alternative is less defensible than the original choice.
Adenoid cystic carcinoma of the breast. Codex, direct analysis; score 8. Nonsignificant standardized incidence ratios (SIRs) were interpreted as an absence of associated cancers.	Interpret the estimates as no statistically detected excess, while acknowledging that the confidence intervals still permit increased risk. Failure to reject the null does not establish absence of excess risk.	**Limited qualification.** The distinction is reasonable, but the paper already qualifies its conclusions with caveats. The reviewer judged this a clarification of interpretation rather than a conclusion-changing result.
Head and neck mucosal melanoma incidence. Claude Code, direct analysis; score 8. Increasing incidence was attributed primarily to nasal-cavity disease.	Directly compare nasal and non-nasal trends rather than infer a difference from their separate significance tests. The analyst reported positive trends in both groups and a nonsignificant interaction ($p = 0.46$).	**Flagged for further review.** The comparison may identify an overstatement, but noisy data and model-fit concerns complicate interpretation. Closer manuscript review and statistical consultation are needed; a nonsignificant interaction does not establish equal trends.

4.3.3 Expert Analysis

One coauthor with medical expertise and familiarity with SEER data manually examined 10 cases scored 7–9 in depth (five each from Paths B and C in Figure 2). Among the 5 cases from the Perturbation Agent, 2 suggested consequential changes, but closer expert scrutiny indicated that the alternatives were likely less defensible than the original analytical choices; the remaining 3 offered only limited qualifications to the papers' conclusions. Among the 5 cases from direct coding agent analysis, 4 likewise offered only limited qualifications. The remaining 1 case identified a potentially overstated comparison between nasal and non-nasal incidence trends, but determining its consequence requires closer manuscript review and statistical consultation. Thus, 9 cases did not establish a consequential change under a defensible alternative, while 1 remains flagged for further review. Table 4 illustrates 3 cases with one from each category: a likely less defensible alternative, a limited qualification to the paper's conclusions, and a potentially consequential issue requiring further review.

Overall, our pipeline narrows the material requiring expert attention by autonomously reconstructing published findings, executing alternative analyses, and prioritizing potentially consequential results. Across 579 fully reproduced findings, it identifies 34 with model-assessed consequential links, providing a focused shortlist and supporting evidence for expert review. Experts can therefore concentrate on whether the flagged alternatives are scientifically defensible and will materially change the conclusions, rather than reconstructing and testing each analysis from scratch manually.

5 Conclusion

We introduced SEER-Repro, a benchmark of 20 published SEER studies, and an AI-assisted pipeline for evaluating reproducibility and robustness to analytical choices. Our reproduction agent recovered 79.1% of atomic claims. Automated robustness assessments then prioritized 34 of 579 fully reproduced findings (5.9%) for expert review, providing a focused shortlist with supporting analytical evidence. Expert examination of 10 flagged cases clarified why 9 did not establish consequential changes under defensible alternatives and identified 1 potentially consequential issue requiring further investigation. These results illustrate how automated analysis can focus expert attention on questions that warrant closer scientific scrutiny.

SEER provides an early, high-stakes testbed for this approach. Longer term, such checks could become part of scientific infrastructure: published findings could be routinely reassessed as data, methods, and analytical alternatives evolve, with potentially consequential sensitivities prioritized for expert review.

AI USE STATEMENT

Uses of generative AI. In this work, we used generative AI tools to help develop theoretical models or conceptual frameworks; propose or refine hypotheses; design or provide feedback on research methodology or experiments; implement methods; clean and reformat datasets; support qualitative and thematic data analysis; interpret results; create or modify scientific figures or images; create or edit software code; draft parts of the paper; create artifacts; summarize or analyze existing literature; discover research topics or identify gaps; brainstorm; source and search for information; improve the paper's readability; identify relevant literature; and format references.

Activities without generative AI. We did not use generative AI tools to suggest experimental parameters, suggest a structure for the paper, or propose a title or keywords.

Activities not applicable to this work. Generating synthetic datasets, formulating mathematical claims, providing critical ingredients for mathematical proofs, assisting with proof writing, translating, formulating survey or interview questions, and transcribing research recordings are not applicable to this work.

Additional disclosure and author responsibility. We have reviewed all AI-assisted work. For example, the final writing has been double-checked by authors. We have reviewed all relevant literature manually found by LLMs. We take responsibility for the final content of this work, including text, claims or artifacts produced with the aid of generative AI.

ETHICS STATEMENT

This work aims to support scientific reliability by evaluating the reproducibility and analytical robustness of published cancer epidemiology findings. We acknowledge that errors in our pipeline, including but not limited to data selection, LLM-generated code, interpretation, and grading, may lead to incorrect assessments. Failure to reproduce a finding may also reflect unavailable historical data (as documented in Section 4.1). Sensitivity to an alternative analysis does not invalidate the original study and requires careful expert judgment to assess its significance (as discussed in Section 4). Our goal is to help experts identify findings that warrant closer examination, making rigorous scientific review more accessible while keeping expert judgment central to the process.

REPRODUCIBILITY STATEMENT

We document the SEER data releases and registry coverage in Appendix A, and the database resources, manuals, source links, and file formats in Appendix B. Table 1 identifies the exact 20 papers evaluated in SEER-Repro. Appendix C provides the research prompts and report-generation settings, while Appendix D describes the analysis implementation and Appendix H provides the LLM prompts. Section 4 identifies the tested analysis models (GPT-5.6 Sol, Opus 4.8, GLM 5.3, and Kimi K3) and the coding-agent configurations used in the comparison experiments.

REFERENCES

Anthropic. Introducing Claude Opus 4.8, May 2026. URL https://www.anthropic.com/news/claude-opus-4-8.

Christina E. Bailey, Chung-Yuan Hu, Y. Nancy You, Brian K. Bednarski, Miguel A. Rodriguez-Bigas, John M. Skibber, Scott B. Cantor, and George J. Chang. Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010. *JAMA Surgery*, 150(1):17–22, 2015. doi: 10.1001/jamasurg.2014.1756.

Martin Bertran, Riccardo Fogliato, and Zhiwei Steven Wu. Many AI Analysts, One Dataset: Navigating the Agentic Data Science Multiverse. *Proceedings of the National Academy of Sciences*, 123(29):e2606495123, 2026. doi: 10.1073/pnas.2606495123.

Rotem Botvinik-Nezer, Felix Holzmeister, Colin F. Camerer, et al. Variability in the analysis of a single neuroimaging dataset by many teams. *Nature*, 582:84–88, 2020. doi: 10.1038/s41586-020-2314-9.

Nate Breznau, Eike Mark Rinke, Alexander Wuttke, et al. Observing many researchers using the same data and hypothesis reveals a hidden universe of uncertainty. *Proceedings of the National Academy of Sciences*, 119(44):e2203150119, 2022. doi: 10.1073/pnas.2203150119.

Abel Brodeur, Derek Mikola, Nikolai Cook, et al. Reproducibility and robustness of economics and political science research. *Nature*, 652:151–156, 2026. doi: 10.1038/s41586-026-10251-x.

Ziru Chen, Shijie Chen, Yuting Ning, Qianheng Zhang, Boshi Wang, Botao Yu, Yifei Li, Zeyi Liao, Chen Wei, Zitong Lu, et al. ScienceAgentBench: Toward Rigorous Assessment of Language Agents for Data-Driven Scientific Discovery. In *International Conference on Learning Representations*, 2025.

Brittany J. Cline, Matthew C. Simpson, Matthew Gropler, Aleksandr R. Bukatko, Eric Adjei Boakye, Kahee A. Mohammed, and Nosayaba Osazuwa-Peters. Change in Age at Diagnosis of Oropharyngeal Cancer in the United States, 1975–2016. *Cancers*, 2020. doi: 10.3390/cancers12113191.

Michael B. Cook, Sanford M. Dawsey, Neal D. Freedman, Peter D. Inskip, Sara M. Wichner, Sabah M. Quraishi, Susan S. Devesa, and Katherine A. McGlynn. Sex Disparities in Cancer Incidence by Period and Age. *Cancer Epidemiology, Biomarkers & Prevention*, 18(4):1174–1182, 2009. doi: 10.1158/1055-9965.epi-08-1118.

Louise Davies and H. Gilbert Welch. Current Thyroid Cancer Trends in the United States. *JAMA Otolaryngology–Head & Neck Surgery*, 140(4):317–322, 2014. doi: 10.1001/jamaoto.2014.1.

Andrew Delios et al. Examining the Generalizability of Research Findings from Archival Data. *Proceedings of the National Academy of Sciences*, 119(30):e2120377119, 2022. doi: 10.1073/pnas.2120377119.

Mingxuan Du, Benfeng Xu, Chiwei Zhu, Xiaorui Wang, and Zhendong Mao. DeepResearch Bench: A Comprehensive Benchmark for Deep Research Agents. *arXiv preprint arXiv:2506.11763*, 2025. URL https://arxiv.org/abs/2506.11763.

H B El-Serag, A C Mason, N Petersen, and C R Key. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. *Gut*, 50(3):368–372, 2002. doi: 10.1136/gut.50.3.368.

Bassam Ghabach, William F Anderson, Rochelle E Curtis, Mark M Huycke, Jackie A Lavigne, and Graça M Dores. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. *Breast Cancer Research*, 2010. doi: 10.1186/bcr2613.

Ken Gu, Ruoxi Shang, Ruien Jiang, Keying Kuang, Richard-John Lin, Donghe Lyu, Yue Mao, Youran Pan, Teng Wu, Jiaqian Yu, Yikun Zhang, Tianmai M. Zhang, Lanyi Zhu, Mike A. Merrill, Jeffrey Heer, and Tim Althoff. BLADE: Benchmarking Language Model Agents for Data-Driven Science. In *Findings of the Association for Computational Linguistics: EMNLP 2024*, 2024.

Gordon H. Guyatt, Andrew D. Oxman, Regina Kunz, Gunn E. Vist, Yngve Falck-Ytter, Holger J. Schünemann, and GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? *BMJ*, 336(7651):995–998, 2008. doi: 10.1136/bmj.39490.551019.BE. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC2364804/.

Kenneth W. Hance, William F. Anderson, Susan S. Devesa, Heather A. Young, and Paul H. Levine. Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. *JNCI: Journal of the National Cancer Institute*, 97(13):966–975, 2005. doi: 10.1093/jnci/dji172.

Xingkang He, Wenrui Wu, Yu'e Ding, Yue Li, Jianmin Si, and Leimin Sun. Excessive risk of second primary cancers in young-onset colorectal cancer survivors. *Cancer Medicine*, 2018. doi: 10.1002/cam4.1437.

Xianglin Hu, Kai Deng, Hui Ye, Zhengwang Sun, Wending Huang, Yangbai Sun, and Wangjun Yan. Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study. *Cancers*, 2021. doi: 10.3390/cancers13215381.

Nicholas L. Hudock, Kyle Mani, Chachrit Khunsriraksakul, Vonn Walter, Larissa Nekhlyudov, Ming Wang, Eric J. Lehrer, Maria R. Hudock, Dajiang J. Liu, Daniel E. Spratt, and Nicholas G. Zaorsky. Future trends in incidence and long-term survival of metastatic cancer in the United States. *Communications Medicine*, 3(1), 2023. doi: 10.1038/s43856-023-00304-x.

Chin Hur, Melecia Miller, Chung Yin Kong, Emily C. Dowling, Kevin J. Nattinger, Michelle Dunn, and Eric J. Feuer. Trends in esophageal adenocarcinoma incidence and mortality. *Cancer*, 119 (6):1149–1158, 2013. doi: 10.1002/cncr.27834.

Ahmedin Jemal, Elizabeth Ward, and Michael J Thun. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. *Breast Cancer Research*, 9(3), 2007. doi: 10.1186/bcr1672.

Scott P. Kelly, Philip S. Rosenberg, William F. Anderson, Gabriella Andreotti, Naji Younes, Sean D. Cleary, and Michael B. Cook. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. *European Urology*, 71(2):195–201, 2017. doi: 10.1016/j.eururo.2016.05.011.

Kimi Team. Kimi K3: Open frontier intelligence. *arXiv preprint arXiv:2607.24653*, 2026. URL https://arxiv.org/abs/2607.24653.

Kai Li, Dan Lu, Yazhou Guo, Changwei Wang, Xiao Liu, Yu Liu, and Dezhong Liu. Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973-2014. *Cancer Medicine*, 2018. doi: 10.1002/cam4.1757.

Minghao Li, Ying Zeng, Zhihao Cheng, Cong Ma, and Kai Jia. ReportBench: Evaluating Deep Research Agents via Academic Survey Tasks. *arXiv preprint arXiv:2508.15804*, 2025.

Dongdong Lin, Ming Wang, Yan Chen, Jie Gong, Liang Chen, Xiaoyong Shi, Fujun Lan, Zhongliang Chen, Tao Xiong, Hu Sun, and Shu Wan. Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018. *Frontiers in Oncology*, 2021. doi: 10.3389/fonc.2021.748061.

M. S. Linet, L. A. G. Ries, M. A. Smith, R. E. Tarone, and S. S. Devesa. Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States. *JNCI Journal of the National Cancer Institute*, 91(12):1051–1058, 1999. doi: 10.1093/jnci/91.12.1051.

Shicheng Liu, Yucheng Jiang, Sajid Farook, Camila Nicollier Sanchez, David Fernando Castro Pena, and Monica S. Lam. DataSTORM: Deep Research on Large-Scale Databases using Exploratory Data Analysis and Data Storytelling. *Conference on Language Modeling*, 2026a.

Wei Liu, Peijie Yu, Michele Orini, Yali Du, and Yulan He. Hunt Instead of Wait: Evaluating Deep Data Research on Large Language Models. *International Conference on Machine Learning*, 2026b.

Bodhisattwa Prasad Majumder, Harshit Surana, Dhruv Agarwal, Bhavana Dalvi Mishra, Abhijeetsingh Meena, Aryan Prakhar, Tirth Vora, Tushar Khot, Ashish Sabharwal, and Peter Clark. DiscoveryBench: Towards Data-Driven Discovery with Large Language Models. In *International Conference on Learning Representations*, 2025.

David M. Marcus, Rebecca P. Marcus, Roshan S. Prabhu, Taofeek K. Owonikoko, David H. Lawson, Jeffrey Switchenko, and Jonathan J. Beitler. Rising Incidence of Mucosal Melanoma of the Head and Neck in the United States. *Journal of Skin Cancer*, 2012. doi: 10.1155/2012/231693.

Rafael Meza, Clare Meernik, Jihyoun Jeon, and Michele L. Cote. Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010. *PLOS ONE*, 2015. doi: 10.1371/journal.pone.0121323.

Jiacheng Miao, Jonathan K. Pritchard, and James Zou. The Agentic Garden of Forking Paths. *arXiv preprint arXiv:2607.01507*, 2026.

Diana J. Moke, Ziwei Song, Lihua Liu, Ann S. Hamilton, Dennis Deapen, and David R. Freyer. A Population-Based Analysis of 30-Year Mortality among Five-Year Survivors of Adolescent and Young Adult Cancer: The Roles of Primary Cancer, Subsequent Malignancy, and Other Health Conditions. *Cancers*, 2021. doi: 10.3390/cancers13163956.

National Cancer Institute. SEER Program Annual Usage Metrics, 2024. https://seer.cancer.gov/about/factsheets/metrics.pdf, 2025. Accessed September 15, 2026.

National Cancer Institute. Behavior Variable Changes. https://seer.cancer.gov/data-software/documentation/seerstat/nov2020/behavior-change.html, 2026a. Accessed September 23, 2026.

National Cancer Institute. SEER Data Change History. https://seer.cancer.gov/data/data-changes.html, 2026b. Accessed September 23, 2026.

National Cancer Institute. U.S. County Population Data, 1969–2024. https://seer.cancer.gov/popdata/, 2026c. Accessed September 23, 2026.

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/, 2026d.

National Cancer Institute. Registry Groupings in SEER Data and Statistics. https://seer.cancer.gov/registries/terms.html, 2026e. Accessed September 23, 2026.

National Cancer Institute. SEER*Stat Database Details: Supplemental SEER November 2020 Submission. https://seer.cancer.gov/data-software/documentation/seerstat/supplemental2020/, 2026f. Accessed September 23, 2026.

OpenAI. GPT-5.6 Sol. Model documentation, 2026. URL https://developers.openai.com/api/docs/models/gpt-5.6-sol.

Liana Patel, Negar Arabzadeh, Harshit Gupta, Ankita Sundar, Ion Stoica, Matei Zaharia, and Carlos Guestrin. DeepScholar-Bench: A Live Benchmark and Automated Evaluation for Generative Research Synthesis. *arXiv preprint arXiv:2508.20033*, 2025. URL https://arxiv.org/abs/2508.20033.

Gaurav Sahu, Abhay Puri, Juan Rodriguez, Amirhossein Abaskohi, Mohammad Chegini, Alexandre Drouin, Perouz Taslakian, Valentina Zantedeschi, Alexandre Lacoste, David Vazquez, Nicolas Chapados, Christopher Pal, Sai Rajeswar Mudumba, and Issam Hadj Laradji. InsightBench: Evaluating Business Analytics Agents Through Multi-Step Insight Generation. *International Conference on Learning Representations*, 2025.

Raphael Silberzahn, Eric L. Uhlmann, Daniel P. Martin, et al. Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results. *Advances in Methods and Practices in Psychological Science*, 1(3):337–356, 2018. doi: 10.1177/2515245917747646.

Uri Simonsohn, Joseph P. Simmons, and Leif D. Nelson. Specification Curve Analysis. *Nature Human Behaviour*, 4:1208–1214, 2020. doi: 10.1038/s41562-020-0912-z.

Sara Steegen, Francis Tuerlinckx, Andrew Gelman, and Wolf Vanpaemel. Increasing Transparency Through a Multiverse Analysis. *Perspectives on Psychological Science*, 11(5):702–712, 2016. doi: 10.1177/1745691616658637.

Sophia S. Wang, Mark E. Sherman, Allan Hildesheim, James V. Lacey, and Susan Devesa. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. *Cancer*, 100(5):1035–1044, 2004. doi: 10.1002/cncr.20064.

Wenyi Xu, Yuren Mao, Xiaolu Zhang, Chao Zhang, Xuemei Dong, Mengfei Zhang, and Yunjun Gao. DAgent: A Relational Database-Driven Data Analysis Report Generation Agent. *arXiv preprint arXiv:2503.13269*, 2025.

Z.ai. GLM-5.3. Model documentation, 2026. URL `https://docs.z.ai/guides/llm/glm-5.3`.

APPENDIX

A SEER Data Evolution and Study Scope **16**

B Supplementary SEER Tables and Manuals **17**

C Details on LLM-Generated Research Reports **21**

D Perturbation Agent: Implementation Details **22**

E Reproduction Outcome Breakdowns in SEER-Repro **24**

F Reproduction Grading Details **24**

F.1 Judge Inputs and Evidence Assessment 24

F.2 Numerical Extraction and Deterministic Comparison 24

F.3 Grading Qualitative Claims 26

G Full Titles of Benchmark Papers **27**

H Prompts Used **28**

A SEER Data Evolution and Study Scope

Changing registry coverage. SEER 9, SEER 13, and SEER 18 identify different geographic cohorts, with standard diagnosis-year coverage beginning in 1975, 1992, and 2000, respectively. Figure 4 summarizes their expansion and subsequent changes. With the November 2021 submission, released in April 2022, Detroit was excluded from the new databases, yielding SEER 8, 12, and 17. Massachusetts was subsequently excluded from the November 2024 submission, changing SEER 22 to SEER 21 (National Cancer Institute, 2026b;e). Replacing an older grouping with its successor changes the study population, even when the same years and disease filters are applied.



Figure 4: Evolution of the SEER registry groupings relevant to our study. Historical SEER 13 and 18 expand the SEER 9 cohort; their successor groupings exclude Detroit. The separately retained SEER 9 supplement covers 1975–2018. Registry memberships and retained coverage follow NCI documentation (National Cancer Institute, 2026e;f).

Why we focus on SEER 9. The supplemental November 2020 database preserves SEER 9 records, including Detroit, through 2018. Its updated population denominators can change rates even though tumor information is unchanged (National Cancer Institute, 2026f). We use this retained cohort and select papers whose analyses do not require additional registries. The newer, Detroit-excluding releases available to our study cannot directly substitute for historical SEER 13 or SEER 18 cohorts; exact reconstruction would require compatible archived inputs.

Release and variable differences remain. Retaining the registry grouping does not guarantee identical historical inputs. For example, the November 2020 submission changed the default malignant-behavior definition and excluded approximately 10,000 previously included, no-longer-reportable borderline cases, predominantly ovarian tumors (National Cancer Institute, 2026a). Our local failure diagnostics also identify unavailable radiation-treatment fields, preventing reconstruction of some treatment proportions even when registry coverage matches. We retain these field-level limitations when interpreting claim-level reproduction outcomes.

B SUPPLEMENTARY SEER TABLES AND MANUALS

The curated local inventory contains one SEER 9 case table, four population denominator tables, 34 SEER*Explorer aggregate tables, and 40 documentation files or reference pages.

Population denominators. The four population tables provide county-level annual estimates by age, sex, and race, with an expanded race/Hispanic-origin scheme available from 1990. Each series is supplied both in 20 age groups and in single-year ages through 89 with a 90+ category (Table 6). These are all-state files: rates for a SEER cohort require restricting them to the corresponding registry counties. The selected years, age bins, race categories, and standard-population weights must also match the analysis. NCI revisions to population estimates and age groupings can change historical rates even when case counts are unchanged (National Cancer Institute, 2026c).

SEER*Explorer aggregates. We include 34 workbooks from the official November 2024 SEER*Explorer archive as queryable tables. Table 6 lists each table with its column count, row count, and description. They supplement case-level computation with statistics whose source or construction differs from the SEER 9 case table. In particular, U.S. mortality tables describe population mortality rather than deaths among patients in the case cohort. Likewise, relative survival, prevalence, and lifetime-risk outputs must be interpreted according to their own definitions.

Manuals and reference definitions. Table 5 lists the 40 documentation resources supplied in SEER-Repro, with the exact source URLs recorded in the local download manifest and their verified file formats: 28 HTML pages, 11 PDFs, and one XLSX spreadsheet. The collection covers SEER*Stat dictionaries, population denominators and standardization, coding and staging, variable recodes, and registry coverage. It includes recent manuals and a historical-manual index; definitions must be matched to the coding rules applicable to each study period.

Table 5: Documentation resources provided in SEER-Repro. Source URLs are those recorded for the local copies; formats were verified from the files.

Resource	Source URL	Format
SEER*Stat resources (6)		
SEER*Stat November 2025 submission overview	https://seer.cancer.gov/data-software/documentation/seerstat/nov2025/	HTML
Variable dictionary spreadsheet for SEER*Stat variables	https://seer.cancer.gov/data-software/documentation/seerstat/nov2025/seerstat-variable-dictionary-nov2025.xlsx	XLSX
Variable dictionary PDF for SEER*Stat variables	https://seer.cancer.gov/data-software/documentation/seerstat/nov2025/seerstat-variable-dictionary-nov2025.pdf	PDF
Text data file description for SEER Research and Research Plus	https://seer.cancer.gov/data-software/documentation/seerstat/nov2025/TextData.FileDescription-nov2025.pdf	PDF
SEER product comparison and availability notes	https://seer.cancer.gov/data/product-comparison.html	HTML
SEER data documentation hub	https://seer.cancer.gov/data-software/documentation/	HTML
Population resources (10)		
U.S. county population data overview	https://seer.cancer.gov/popdata/	HTML
Population data download page and file layout links	https://seer.cancer.gov/popdata/download.html	HTML
Population data dictionary for fixed-width fields	https://seer.cancer.gov/popdata/popdic.html	HTML
Single-year-age population estimate methodology	https://seer.cancer.gov/popdata/singleages.html	HTML
NCI modifications to county population estimates	https://seer.cancer.gov/popdata/modifications.html	HTML

Continued on next page

Table 5 (continued)

Resource	Source URL	Format
Katrina/Rita population adjustment notes	https://seer.cancer.gov/popdata/hurricane_adj.html	HTML
Woods & Poole technical documentation linked by SEER	https://seer.cancer.gov/popdata/W%26P_ICen_Tech_Documentation.pdf	PDF
U.S. populations hub	https://seer.cancer.gov/data-software/uspopulations.html	HTML
Standard population data hub	https://seer.cancer.gov/stdpopulations/	HTML
Use of the 2000 U.S. standard population	https://seer.cancer.gov/stdpopulations/2000stdpop-use.html	HTML
Coding and staging (10)		
SEER coding and staging manual page	https://seer.cancer.gov/tools/codingmanuals/	HTML
Historical coding manuals index	https://seer.cancer.gov/tools/codingmanuals/historical.html	HTML
2025 SEER Program Coding and Staging Manual	https://seer.cancer.gov/manuals/2025/SPCSM_2025_MainDoc.pdf	PDF
2025 county codes	https://seer.cancer.gov/manuals/2025/SPSCM_2025_Appendix_A.pdf	PDF
2025 country and state codes	https://seer.cancer.gov/manuals/2025/SPCSM_2025_Appendix_B.pdf	PDF
2025 race and nationality descriptions	https://seer.cancer.gov/manuals/2025/SPCSM_2025_Appendix_D.pdf	PDF
2025 reportable and non-reportable examples	https://seer.cancer.gov/manuals/2025/SPCSM_2025_Appendix_E.pdf	PDF
2025 summary of changes	https://seer.cancer.gov/manuals/2025/SPCSM_2025_Changelog.pdf	PDF
2026 SEER Program Coding and Staging Manual	https://seer.cancer.gov/manuals/2026/SPCSM_2026_MainDoc.pdf	PDF
2026 county codes	https://seer.cancer.gov/manuals/2026/SPSCM_2026_Appendix_A.pdf	PDF
Variable and recode definitions (10)		
Variable and recode definitions hub	https://seer.cancer.gov/analysis/	HTML
Site recode documentation	https://seer.cancer.gov/siterecode/	HTML
Incidence site recode variables	https://seer.cancer.gov/analysis/incidence.html	HTML
Cause of death recode	https://seer.cancer.gov/codrecode/	HTML
Cause-specific death classification	https://seer.cancer.gov/causespecific/	HTML
Race and Hispanic ethnicity definitions	https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/	HTML
Cancer stage variable overview	https://seer.cancer.gov/analysis/stage.html	HTML
Summary Stage 2018 documentation	https://seer.cancer.gov/tools/ssm/	HTML
Months survived based on complete dates	https://seer.cancer.gov/survivaltime/	HTML
Tumor size over time recode	https://seer.cancer.gov/tumorsize/	HTML
Registry coverage (4)		
SEER registries overview	https://seer.cancer.gov/registries/	HTML
List of SEER registries	https://seer.cancer.gov/registries/list.html	HTML
Registry groupings used in SEER data and statistics	https://seer.cancer.gov/registries/terms.html	HTML
Population characteristics of SEER registry areas	https://seer.cancer.gov/registries/characteristics.html	HTML

Table 6: The 39 curated tables, with schema column counts and loaded row counts. SEER*Explorer tables use the November 2024 archive; RUCC denotes rural–urban continuum codes.

Table	Cols.	Rows	Description
SEER 9 case records	250	5,075,266	Case-level cancer-registry export from the SEER 9 Program.
Population 1969–2024, 20 age groups	13	17,485,723	County denominators; White/Black/Other.
Population 1990–2024, 20 age groups	13	22,178,259	County denominators; expanded race/Hispanic origin.
Population 1969–2024, single-year ages	13	69,655,933	County denominators; White/Black/Other.
Population 1990–2024, single-year ages	13	78,667,287	County denominators; expanded race/Hispanic origin.
Recent trends annual SEER incidence rates	13	1,648,320	Annual incidence rates.
Recent trends SEER incidence trend estimates	17	104,360	Incidence trend estimates.
5-year age adjusted incidence rates	11	67,360	Five-year age-adjusted incidence rates.
Long-term trends annual SEER incidence rates	12	488,160	Annual incidence rates.
Long-term trends SEER incidence trend estimates	16	38,815	Incidence trend estimates.
Incidence rates by age at diagnosis	12	59,360	Incidence rates stratified by age at diagnosis.
Stage distribution	8	51,440	Stage distribution.
Median age at diagnosis	6	1,592	Median age at diagnosis estimates.
Recent trends annual SEER incidence rates by RUCC	13	20,700	Annual incidence rates by rural–urban category.
Recent trends SEER incidence trend estimates by RUCC	17	3,832	Incidence trend estimates by rural–urban category.
5-year age adjusted incidence rates by RUCC	11	900	Five-year age-adjusted incidence rates by rural–urban category.
Recent trends annual U.S. mortality rates	11	218,880	Annual U.S. mortality rates.
Recent trends U.S. mortality trend estimates	15	30,836	U.S. mortality trend estimates.
5-year age adjusted mortality rates	10	9,120	Five-year age-adjusted mortality rates.
Long-term trends annual U.S. mortality rates	11	167,580	Annual U.S. mortality rates.
Long-term trends U.S. mortality trend estimates	15	14,939	U.S. mortality trend estimates.
Mortality rates by age at death	10	18,240	Mortality rates stratified by age at death.
Median age at death	6	912	Median age at death estimates.
Recent trends annual U.S. mortality rates by RUCC	13	12,096	Annual U.S. mortality rates by rural–urban category.
Recent trends U.S. mortality trend estimates by RUCC	17	1,957	U.S. mortality trend estimates by rural–urban category.
5-year age adjusted mortality rates by RUCC	11	612	Five-year age-adjusted mortality rates by rural–urban category.
Recent trends annual SEER survival rates	14	631,440	Annual SEER survival rates.
Recent trends SEER survival trend estimates	15	39,890	Survival trend estimates.
5-year relative survival	12	66,640	Five-year relative survival estimates.
Long-term trends annual SEER survival rates	13	48,504	Annual SEER survival rates.
Long-term trends SEER survival trend estimates	14	2,184	Survival trend estimates.
Conditional survival	12	260,160	Conditional survival estimates.
Survival by survival time	12	715,440	Survival estimates by survival-time interval.
Complete prevalence	7	752	Prevalence.

Continued on next page

Table 6 (continued)

Table	Cols.	Rows	Description
Limited duration prevalence	9	103,920	Prevalence.
Risk of diagnosis	9	179,520	Risk-of-diagnosis estimates.
Risk of death	9	179,520	Risk-of-death estimates.
Preliminary estimates annual SEER incidence rates	13	4,200	Preliminary annual incidence rates.
Preliminary estimates SEER incidence trend estimates	17	799	Preliminary incidence trend estimates.

C Details on LLM-Generated Research Reports

For each of the 20 cases in SEER-Repro, we supply the same neutral research prompt to two coding agents: Claude Code with Opus at the maximum effort setting, and Codex with GPT-5.6 Sol at the xhigh effort setting. Both agents have access to all databases and manuals included in SEER-Repro. The prompts specify the research topic and scope without supplying the published findings. Table 7 lists the exact neutral prompt used for each case.

Table 7: Neutral research prompts supplied to both report-generation agents for the 20 benchmark cases, in the same paper order as Table 1.

Paper (shorter name)	Neutral research prompt
Bone sarcoma survival by tumor site	Analyze tumor-site-specific survival trends for bone sarcomas in SEER 9 from 1980 to 2018, especially variation by histology, site, stage, age, and calendar period.
Sex disparities in cancer incidence	Analyze sex disparities in cancer incidence across SEER 9 from 1975 to 2004, especially male-to-female incidence rate ratios by cancer site, histology, period, and age.
Inflammatory breast cancer incidence and survival	Analyze inflammatory breast carcinoma incidence and survival trends in SEER 9 from 1988 to 2000, especially differences from locally advanced and non-T4 breast cancer by race and subtype.
Fatal prostate cancer incidence by race	Analyze trends in the incidence of fatal prostate cancer in the United States from 1975 to 2002, especially differences by race and age and changes following the introduction of PSA screening.
Thyroid cancer trends	Analyze thyroid cancer incidence and mortality trends in the United States from 1975 to 2009, especially by tumor size, stage, histology, age, sex, and race.
Age at oropharyngeal cancer diagnosis	Analyze changes in age at diagnosis of oropharyngeal cancer in SEER 9 from 1975 to 2016, especially by sex, race, and human-papillomavirus-related tumor site.
Childhood cancer incidence and mortality	Analyze childhood cancer incidence and mortality trends in the United States from 1975 to 1995, especially by International Classification of Childhood Cancer diagnostic group.
Esophageal adenocarcinoma incidence and mortality	Analyze temporal trends in esophageal adenocarcinoma incidence and incidence-based mortality in the United States from 1975 to 2009, especially by cancer stage, sex, and race.
Adenoid cystic carcinoma of the breast	Analyze breast adenoid cystic carcinoma in SEER 9 from 1977 to 2006, especially incidence, clinicopathologic characteristics, subsequent primary cancers, and relative survival.
Adult diffuse glioma incidence	Analyze incidence trends in adult diffuse gliomas in SEER 9 from 1973 to 2014, especially differences between glioblastoma and nonglioblastoma and their age, period, and birth-cohort effects.
Head and neck mucosal melanoma incidence	Analyze incidence and survival trends for mucosal melanoma of the head and neck in SEER 9 from 1987 to 2009, especially by anatomic site, age, sex, race, and stage.
Second cancers after young-onset colorectal cancer	Analyze the risk of second primary cancers among young-onset colorectal cancer survivors in SEER 9 from 1973 to 2013, including standardized incidence ratios and absolute excess risks.
Age disparities in colorectal cancer incidence	Analyze age-related disparities in colon and rectal cancer incidence trends in the United States from 1975 to 2010, especially differences between young adults and older patients by stage.
Lung cancer incidence by sex, race, and histology	Analyze lung cancer incidence trends in SEER 9 from 1973 to 2010, especially differences by sex, race, histology, and stage distribution.

Continued on next page

Table 7 continued

Paper (shorter name)	Neutral research prompt
Intracranial glioma incidence and mortality	Analyze intracranial glioma incidence, incidence-based mortality, and relative survival trends in SEER 9 from 1975 to 2018, especially by histology, age, sex, race, and tumor characteristics.
Long-term mortality in young cancer survivors	Analyze 30-year mortality among five-year survivors of adolescent and young adult cancer diagnosed in SEER 9 from 1975 to 2012, distinguishing primary cancer, subsequent malignancy, and other causes of death.
Esophageal versus gastric cardia adenocarcinoma	Analyze epidemiologic differences between esophageal adenocarcinoma and gastric cardia adenocarcinoma in the nine SEER population-based registries from 1977 to 1996, especially temporal, ethnic, age, and birth-cohort patterns.
Breast cancer incidence by age and tumor features	Analyze recent trends in female breast cancer incidence in the United States, especially by age group, tumor size, stage, and estrogen/progesterone receptor status.
Metastatic cancer incidence and survival	Analyze incidence trends and long-term survival of metastatic cancer in the United States from 1988 to 2018, especially trends in metastasis to specific sites such as liver, lung, bone, and brain.
Cervical cancer incidence by race and histology	Analyze cervical adenocarcinoma and squamous cell carcinoma incidence trends among white and black women in the United States from 1976 to 2000, especially by histology, age, race, and disease stage.

D PERTURBATION AGENT: IMPLEMENTATION DETAILS

We implement the components in Section 3.2.2 with LLM calls and coding agents. This appendix describes their inputs, prompts, configuration, and the validation controls applied at each stage. Section 4 reports the models evaluated. Our experiments include a published paper and Sol- and Opus-generated reports for each research question; Appendix C documents report generation.

The semantic-call wrapper can request a corrected complete JSON object after schema or parsing failures (Prompt 29).

Eligible findings. For a paper p, we use the fully reproduced findings F_p^{rep} defined in Equation 1. Only these fully reproduced findings enter the analysis. For each paper p, we supply the paper text, its fully reproduced findings F_p^{rep}, and the reproduction evidence E_p to an LLM (Prompt 7), which returns a set of candidate analytical choices from the paper, such as cohort definitions, endpoints, subgroup definitions, model choices, or interpretation rules.

Extracting choices from generated reports. For each additional report r, a separate LLM receives the report, its available query or execution log, and the eligible findings and research-question context from the published paper p; it extracts candidate analytical choices from that report and links them to eligible finding identifiers where applicable (Prompt 8).

Candidate extraction uses ten analytical-choice families: population, measurement, time, missingness, denominator, endpoint, model, inference, subgroup, and interpretation. The implementation verifies finding identifiers and checks supporting quotations against the supplied source text. A repair call receives invalid candidates and validation errors (Prompt 9); deterministic normalization resolves supported quotation differences, and evidence or candidates that remain ungrounded are removed.

Select Analytical Choices. (Step 1 of the Perturbation Agent in Figure 2) Our pipeline can analyze a single paper or optionally consolidate analytical choices from additional reports addressing the same research question into a shared set of analytical choices. This shared set allows us to compare how different reports justify their analytical choices and how their conclusions respond to the same alternatives. In our experiments, we include Sol- and Opus-generated reports addressing the same research question as each published paper (Appendix C). The choice-selection LLM then receives the candidate choices from the published paper and any additional reports together. It merges candidates that describe the same scientific decision and ranks the resulting choices prospectively,

before any alternative analysis has been run (Prompt 10). The ranking considers scientific importance, uncertainty, feasibility, and redundancy, and freezes at most 20 choices per paper. Together, extraction, merging, and ranking implement the Select Analytical Choices stage in Section 3.2.2 and Algorithm 1, returning the choice set $\mathcal{C}_p$. We validate the selected choices and resolve review objections before running alternative analyses.

A review LLM checks the proposed choices for invalid finding links, unsupported quotations, redundancy, and coverage gaps (Prompt 11). Repair calls receive the proposed choices and identified problems, followed by re-review; final repair and resolution calls handle persistent objections (Prompts 12, 13, 14, and 15). If objections remain after these bounded steps, execution stops unless a validated operator resolution tied to that review is supplied. The saved resolution and a hash identify the finalized choice set. These calls provide procedural review rather than independent expert validation.

Propose Alternatives. (Step 2 of the Perturbation Agent in Figure 2) For each selected analytical choice, an LLM examines how each paper or report implements that choice, using the source text and available execution evidence (Prompt 16) and documents the exact setting. Using these original settings and findings, another LLM proposes a defensible alternative to test across sources, adding a second only when it represents a materially different approach (Prompt 18). A separate LLM reviews whether each proposed alternative is scientifically justified and identifies any conditions required for its use before execution (Prompt 20). Choices without a defensible alternative are not tested. The Propose Alternatives stage in Algorithm 1 combines identification of the baseline settings with alternative generation to construct the proposed comparisons $\mathcal{K}_p$: each (k, v) tests alternative v for choice $k \in \mathcal{C}_p$.

Stage-specific repair calls correct invalid baseline mappings, alternatives, or alternative reviews using the associated validation errors (Prompts 17, 19, and 21). Deterministic checks enforce valid identifiers and complete coverage of the required records.

Execute Analyses. (Step 3 of the Perturbation Agent in Figure 2) For each choice–alternative comparison $(k, v) \in \mathcal{K}_p$, the planning LLM receives the baseline settings, the reviewed alternative, linked findings, feasibility conditions, and execution evidence; it decides whether the comparison should be executed and draws up a concrete plan for its implementation (Prompt 22). Invalid plans are repaired against the validation errors, with deterministic checks of identifiers and comparison coverage (Prompt 23). Executable comparisons are then fed to coding agents for implementation (Prompt 24). The executor first runs the baseline unchanged and checks it against the frozen validation criteria. It then copies the baseline, changes only the specified choice and its listed dependent calculations, and saves the baseline output, alternative output, validation evidence, and exact code diff. These saved artifacts form the comparison evidence $e_k(v)$ returned by the Execute Analyses stage in Algorithm 1.

The executor launch supplies schema information, manuals, and read-only data access alongside the execution task (Prompt 28). To recover an implementation, the executor first uses captured executable work, then structured execution traces, then legacy transcripts; it reconstructs the analysis only when none survives. Saved code files have hashes, and evidence paths must resolve to files supplied for review. Interpretation-family jobs use a frozen deterministic rubric.

Coding-agent runtimes receive additional task instructions: the chat-based executor uses a tool-use system message and a missing-output reminder (Prompts 30 and 31); the Codex wrapper can resume a stopped session and finally require completion from existing evidence, marking unfinished comparisons `Unavailable` (Prompts 26 and 27). These are conditional control paths, not extra scientific stages run on every paper. Saved requests and outputs distinguish actual calls from available fallback templates.

Assess Consequences. (Step 4 of the Perturbation Agent in Figure 2) A separate assessment LLM receives each comparison, its eligibility evidence, frozen comparison criteria, and the saved execution evidence $e_k(v)$ (Prompt 25). This implements the Assess Consequences stage in Algorithm 1, assigning an outcome $y_k(v)$ using the `AnalysisOutcome` type defined in Equation 2.

For `DirectChange` outcomes, a further LLM call assigns a scientific-consequence score from 1 to 9 based on the report's conclusions and the baseline-to-alternative evidence (Prompt 33), adapted

from GRADE's nine-point outcome-importance framework (Guyatt et al., 2008). The score bands are interpreted as described in Section 3.2.2.

E Reproduction Outcome Breakdowns in SEER-Repro

Table 8 provides the counts and percentages for all three reproduction outcomes for each paper, alongside its numbers of findings and atomic claims.

Table 9 reports the 20-paper breakdown using cumulative 1%, 5%, and 10% thresholds for quantitative claims and binary outcomes for qualitative claims. Of 1,694 quantitative claims, 1,323 are reproduced (78.1%), 78 are close, and 293 are not reproduced. Of 496 qualitative claims, 409 are reproduced (82.5%) and 87 are not reproduced. Together these yield the 1,732 reproduced, 78 close, and 380 not-reproduced claims reported in the main text.

F Reproduction Grading Details

The reproduction grader separates evidence assessment from numerical comparison. An LLM extracts the result reported for each atomic claim and assesses its method and answer provenance (Prompt 5); deterministic code then applies the numerical grading policy. The reproduction agent's own statement that a finding was reproduced does not determine the final verdict.

F.1 Judge Inputs and Evidence Assessment

Inputs and unit of assessment. One judge call receives the reproduction report for an original finding together with its atomic targets. Each target includes its identifier, claim text, reference answer, numerical or semantic evaluation mode, verification target, source quotation, and required analytical assumptions. The judge is instructed to assess every atomic target independently: reproducing one component of a finding does not establish that its other components were reproduced. The grading call receives the report and structured targets, rather than independently inspecting the complete code and execution trace or rerunning the analysis.

Result availability. For each target, the judge records whether the requested result is reported, not reported, or unclear. A missing reproduction report is assigned a not-reproduced verdict directly. When a report exists but omits the requested result or provides ambiguous evidence, the target likewise receives no reproduction credit.

Method validity. The judge assesses whether the reported computation uses a valid method for the specific target. This includes compatibility with required cohort bounds, disease and variable coding, outcome measures, grouping, denominators, standardization conventions, temporal data definitions, and statistical-model settings. A conflicting analytical assumption makes the method invalid; insufficient methodological evidence makes it unclear. The report need not repeat every required assumption verbatim, but it must establish a compatible computation. Both invalid and unclear methods lead to a not-reproduced verdict, even when the extracted numerical value matches the reference.

Answer provenance. The judge also flags evidence that the result was obtained by recalling, copying, or searching for the published answer instead of computing it from the supplied data. Such results receive no reproduction credit. Consulting documentation, variable definitions, or coding guidance is permitted when the agent subsequently performs the computation. An exact numerical match alone is not evidence of copying. Conversely, the absence of an explicit copying flag does not compensate for an invalid or insufficiently documented method.

F.2 Numerical Extraction and Deterministic Comparison

Structured extraction. For numerical targets, the LLM returns the computed values, their units, and their relations ($=$, $<$, $\leq$, $>$, or $\geq$), preserving unrounded values when available. It does not calculate relative error or assign the final numerical verdict. Values are extracted in the order of the required target components. A reported interval requires its two endpoints, whereas an acceptable-interval target requires the single computed value being tested against the bounds. Optional uncertainty

Table 8: Tabular breakdown of the reproduction outcomes shown in Table 1, in the same paper order. Each outcome cell gives the number of atomic claims and the percentage of that paper's atomic claims. Findings counts refer to distinct parent findings represented by these claims.

Paper (shorter name)	Findings	Atomic claims	Reproduced	Close	Not reproduced
Bone sarcoma survival by tumor site	56	188	187 (99.5%)	0 (0.0%)	1 (0.5%)
Sex disparities in cancer incidence	36	153	146 (95.4%)	1 (0.7%)	6 (3.9%)
Inflammatory breast cancer incidence and survival	40	131	118 (90.1%)	2 (1.5%)	11 (8.4%)
Fatal prostate cancer incidence by race	32	64	57 (89.1%)	2 (3.1%)	5 (7.8%)
Thyroid cancer trends	33	91	78 (85.7%)	1 (1.1%)	12 (13.2%)
Age at oropharyngeal cancer diagnosis	75	154	129 (83.8%)	9 (5.8%)	16 (10.4%)
Childhood cancer incidence and mortality	52	139	115 (82.7%)	6 (4.3%)	18 (12.9%)
Esophageal adenocarcinoma incidence and mortality	33	53	43 (81.1%)	4 (7.5%)	6 (11.3%)
Adenoid cystic carcinoma of the breast	51	128	103 (80.5%)	2 (1.6%)	23 (18.0%)
Adult diffuse glioma incidence	60	111	89 (80.2%)	4 (3.6%)	18 (16.2%)
Head and neck mucosal melanoma incidence	20	54	42 (77.8%)	1 (1.9%)	11 (20.4%)
Second cancers after young-onset colorectal cancer	59	124	95 (76.6%)	14 (11.3%)	15 (12.1%)
Age disparities in colorectal cancer incidence	27	70	52 (74.3%)	7 (10.0%)	11 (15.7%)
Lung cancer incidence by sex, race, and histology	36	111	80 (72.1%)	7 (6.3%)	24 (21.6%)
Intracranial glioma incidence and mortality	67	94	66 (70.2%)	2 (2.1%)	26 (27.7%)
Long-term mortality in young cancer survivors	62	178	123 (69.1%)	5 (2.8%)	50 (28.1%)
Esophageal versus gastric cardia adenocarcinoma	34	54	36 (66.7%)	2 (3.7%)	16 (29.6%)
Breast cancer incidence by age and tumor features	31	74	46 (62.2%)	3 (4.1%)	25 (33.8%)
Metastatic cancer incidence and survival	51	101	59 (58.4%)	5 (5.0%)	37 (36.6%)
Cervical cancer incidence by race and histology	46	118	68 (57.6%)	1 (0.8%)	49 (41.5%)
Total	**901**	**2,190**	**1,732 (79.1%)**	**78 (3.6%)**	**380 (17.4%)**

Table 9: Atomic reproduction outcomes by claim type for the 20-paper SEER-Repro benchmark.

		Quantitative claims				Qualitative claims	
Paper	Cit.	$\leq 1\%$	$\leq 5\%$	$\leq 10\%$	All	Reprod.	Not reprod.
Bone sarcoma survival by tumor site	37	119 (88.1%)	135 (100.0%)	135 (100.0%)	135 (100.0%)	52 (98.1%)	1 (1.9%)
Sex disparities in cancer incidence	466	87 (75.0%)	114 (98.3%)	115 (99.1%)	116 (100.0%)	32 (86.5%)	5 (13.5%)
Inflammatory breast cancer incidence and survival	702	80 (76.2%)	99 (94.3%)	101 (96.2%)	105 (100.0%)	19 (73.1%)	7 (26.9%)
Fatal prostate cancer incidence by race	111	39 (83.0%)	41 (87.2%)	43 (91.5%)	47 (100.0%)	16 (94.1%)	1 (5.9%)
Thyroid cancer trends	1,628	50 (59.5%)	72 (85.7%)	73 (86.9%)	84 (100.0%)	6 (85.7%)	1 (14.3%)
Age at oropharyngeal cancer diagnosis	29	101 (73.2%)	117 (84.8%)	126 (91.3%)	138 (100.0%)	12 (75.0%)	4 (25.0%)
Childhood cancer incidence and mortality	438	62 (57.9%)	90 (84.1%)	96 (89.7%)	107 (100.0%)	25 (78.1%)	7 (21.9%)
Esophageal adenocarcinoma incidence and mortality	510	17 (45.9%)	27 (73.0%)	31 (83.8%)	37 (100.0%)	16 (100.0%)	0 (0.0%)
Adenoid cystic carcinoma of the breast	188	75 (64.7%)	92 (79.3%)	94 (81.0%)	116 (100.0%)	11 (91.7%)	1 (8.3%)
Adult diffuse glioma incidence	72	56 (65.9%)	67 (78.8%)	71 (83.5%)	85 (100.0%)	22 (84.6%)	4 (15.4%)
Head and neck mucosal melanoma incidence	83	28 (56.0%)	38 (76.0%)	39 (78.0%)	50 (100.0%)	4 (100.0%)	0 (0.0%)
Second cancers after young-onset colorectal cancer	43	31 (32.3%)	70 (72.9%)	84 (87.5%)	96 (100.0%)	25 (89.3%)	3 (10.7%)
Age disparities in colorectal cancer incidence	1,102	19 (40.4%)	29 (61.7%)	36 (76.6%)	47 (100.0%)	23 (100.0%)	0 (0.0%)
Lung cancer incidence by sex, race, and histology	368	51 (52.0%)	69 (70.4%)	76 (77.6%)	98 (100.0%)	11 (84.6%)	2 (15.4%)
Intracranial glioma incidence and mortality	116	53 (58.2%)	63 (69.2%)	65 (71.4%)	91 (100.0%)	3 (100.0%)	0 (0.0%)
Long-term mortality in young cancer survivors	23	65 (47.1%)	98 (71.0%)	103 (74.6%)	138 (100.0%)	25 (62.5%)	15 (37.5%)
Esophageal versus gastric cardia adenocarcinoma	266	11 (37.9%)	14 (48.3%)	16 (55.2%)	29 (100.0%)	22 (88.0%)	3 (12.0%)
Breast cancer incidence by age and tumor features	352	19 (37.3%)	26 (51.0%)	29 (56.9%)	51 (100.0%)	20 (87.0%)	3 (13.0%)
Metastatic cancer incidence and survival	68	11 (16.9%)	29 (44.6%)	34 (52.3%)	65 (100.0%)	30 (83.3%)	6 (16.7%)
Cervical cancer incidence by race and histology	448	25 (42.4%)	33 (55.9%)	34 (57.6%)	59 (100.0%)	35 (59.3%)	24 (40.7%)
Total		**999 (59.0%)**	**1,323 (78.1%)**	**1,401 (82.7%)**	**1,694 (100.0%)**	**409 (82.5%)**	**87 (17.5%)**

components are excluded from the required comparisons. The judge preserves the requested representation of change: for example, a signed annual percentage change of -1.09 becomes 1.09 when the target explicitly asks for the magnitude of a decline, but retains its sign when the target asks for a signed change.

Only targets with a reported result, a valid method, and no disallowed answer provenance proceed to numerical comparison. The code applies the following rules:

- **Ordinary point estimates.** For a nonzero reference value t and extracted value x, relative error is $|x - t|/|t|$. Error at most 0.05 is reproduced; error above 0.05 and at most 0.10 is close; larger error is not reproduced. Under the relative rule, a zero target requires an exact zero match unless the reported-precision rule applies. Count-valued targets without an explicit component tolerance also use the relative policy; an integer count does not automatically require exact equality.
- **Reported precision.** If a target specifies d reported decimal places, an absolute difference no greater than $\frac{1}{2}10^{-d}$ is accepted as reproduced before applying the designated tolerance. This allows an unrounded computation to agree with a rounded published result.
- **Exact and absolute tolerances.** Explicit component tolerances take precedence over the default relative thresholds. Exact numerical comparators require equality, subject to the reported-precision check when specified; absolute-tolerance components compare $|x - t|$ with their designated reproduced and close thresholds.
- **Inequalities.** A point estimate must satisfy the target inequality. If the report supplies only a bound, that bound must logically imply the target bound. For example, a computed $p = 0.00002$ satisfies a target $p < 0.001$ without requiring numerical proximity to 0.001. A reported bound alone does not establish a required point value. These comparisons produce reproduced or not-reproduced verdicts rather than a close category.
- **Intervals.** An acceptable-interval target checks whether one computed scalar satisfies both boundaries, respecting strict or inclusive inequalities. A reported interval instead compares its required endpoints separately under their designated rules.
- **Units and multiple components.** Unit labels are normalized before comparison, and explicit scale mismatches, such as a proportion versus a percentage or a count versus a rate, are rejected. Missing unit labels do not independently trigger rejection by this comparator. Required components are paired in their declared order, and the least favorable component verdict determines the atomic verdict. Missing or unparseable required values produce an unclear numerical result, which the final policy converts to not reproduced.

F.3 Grading Qualitative Claims

For qualitative or categorical claims, the judge determines whether the reproduced result supports the same conclusion as the published claim. A claim is marked reproduced only when the conclusions are equivalent and the evidence passes the availability, method-validity, and answer-provenance checks described above. Approximately equivalent, conflicting, or unclear conclusions are marked not reproduced. Unlike numerical claims, qualitative claims have no close category.

Implementation checks and saved records. The implementation verifies that the judge returns the requested claim identifiers and that extracted numerical results have the required structure. Saved records include the extracted result, assessment fields, rationale, final verdict, and grading-policy version. Numerical thresholds can therefore be reapplied to saved extractions without another judge call. Table 9 reports outcomes by claim type.

Scope of the grades. These grades assess whether the reproduction report provides sufficient evidence for the original claim. They do not independently verify the complete analysis code or establish that undocumented analytical choices match those of the original authors.

G FULL TITLES OF BENCHMARK PAPERS

Table 10 maps the shorter names used in Table 1 to the full titles of all 20 papers in SEER-Repro, in the same order.

Table 10: Full titles corresponding to the shorter paper names in Table 1.

Shorter name	Full paper title
Bone sarcoma survival by tumor site	Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study
Sex disparities in cancer incidence	Sex Disparities in Cancer Incidence by Period and Age
Inflammatory breast cancer incidence and survival	Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
Fatal prostate cancer incidence by race	Trends in the Incidence of Fatal Prostate Cancer in the United States by Race
Thyroid cancer trends	Current Thyroid Cancer Trends in the United States
Age at oropharyngeal cancer diagnosis	Change in Age at Diagnosis of Oropharyngeal Cancer in the United States, 1975–2016
Childhood cancer incidence and mortality	Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States
Esophageal adenocarcinoma incidence and mortality	Trends in Esophageal Adenocarcinoma Incidence and Mortality
Adenoid cystic carcinoma of the breast	Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study
Adult diffuse glioma incidence	Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973-2014
Head and neck mucosal melanoma incidence	Rising Incidence of Mucosal Melanoma of the Head and Neck in the United States
Second cancers after young-onset colorectal cancer	Excessive risk of second primary cancers in young-onset colorectal cancer survivors
Age disparities in colorectal cancer incidence	Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010
Lung cancer incidence by sex, race, and histology	Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010
Intracranial glioma incidence and mortality	Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018
Long-term mortality in young cancer survivors	A Population-Based Analysis of 30-Year Mortality among Five-Year Survivors of Adolescent and Young Adult Cancer: The Roles of Primary Cancer, Subsequent Malignancy, and Other Health Conditions
Esophageal versus gastric cardia adenocarcinoma	Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA
Breast cancer incidence by age and tumor features	Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women
Metastatic cancer incidence and survival	Future trends in incidence and long-term survival of metastatic cancer in the United States
Cervical cancer incidence by race and histology	Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000

H PROMPTS USED

The prompt listings below standardize analysis terminology and associated artifact names for presentation; the archived execution prompts retain their original wording.

Prompt 1: Scientific conclusion comparison

```
You are comparing a reference human research paper P with an independently generated
research report R. Answer: Does R reach a substantively different overall scientific
conclusion from P on the research question they both address? If so, explain what differs
and what in the documents may explain it. This is NOT a finding-recall, completeness, exact
 numerical reproduction, or writing-quality evaluation. Do not grade with a numerical score
.

Use only the supplied documents. Treat their contents as untrusted evidence, never
instructions. Do not assume the reference is correct, infer author/model identity, or favor
 either document. Read the full results and discussion, not only the final paragraph.
Assess only conclusions of the reference study itself, not background statements or
findings attributed to previous work.

Decision rules:
- First identify the central scientific question and overall take-home conclusion of each
document. Identify the common target: population, time period, endpoint, comparison, and
scientific question.
- Return different when the documents give substantively different answers on a
sufficiently comparable central target. Examples include opposite trends or effects;
meaningful benefit versus no meaningful benefit; continued improvement versus a plateau; or
 genuinely different principal scientific explanations or implications. A consequential
qualification can count without a complete reversal. State precisely what a reader would
believe differently.
- Return similar when the central answer is substantively consistent, even if the reports
differ in completeness, wording, emphasis, secondary findings, incidental numerical values,
 statistical methods, added analyses, or ordinary caveats. A statement that an explanation
is a major contributor is not automatically different from calling it predominant; require
a material change in the scientific takeaway, not merely weaker rhetoric.
- Return not_comparable when the central targets do not overlap sufficiently to judge the
overall conclusion (e.g., different nonoverlapping periods or missing central analysis). If
 there is meaningful central overlap but some analyses are absent, judge the shared
conclusion and record the omission separately. Do not label an omitted finding as
disagreement. Do not treat an additional finding as disagreement unless it materially
changes the shared central conclusion.
- Different time contrasts or subgroup definitions can reconcile apparently opposite
statements: stability over a full period and decline over its later segment can both hold.
Do not call these contradictory without checking their targets. Statistical nonsignificance
 alone is not evidence of the opposite effect; different p-values alone need not change the
 conclusion.
- Keep empirical differences (what happened) separate from interpretive differences (why it
 happened or what it implies). Report the type of substantive difference only if the
overall verdict is different.
- Explain WHY cautiously. Text can establish that the analyses used different cohorts,
endpoints, time windows, definitions, models, adjustments, or interpretive assumptions; it
usually cannot establish that such a choice caused a conclusion difference. Separate a
documented analytical difference from a plausible causal explanation. Do not speculate
about coding errors, model bias, missing variables, or mechanisms absent from the documents
. Use insufficient_information when the reason cannot be established. This exercise does
not validate execution or establish which conclusion is true.

Return only JSON with this exact structure:
{
 "verdict": "similar" | "different" | "not_comparable",
 "human_takeaway": "Brief central conclusion of the current reference study.",
 "report_takeaway": "Brief central conclusion of the report.",
 "shared_question_and_scope": "What can actually be compared, including material scope
differences.",
 "difference_type": "none" | "empirical" | "interpretive" | "both" | "not_comparable",
 "substantive_differences": [
  {
   "difference": "A material difference in the shared central conclusion, not merely an
omitted or secondary finding.",
   "type": "empirical" | "interpretive",
   "human_quote": "Short contiguous verbatim reference passage.",
   "report_quote": "Short contiguous verbatim report passage.",
   "why_material": "What a reader would conclude differently and why this is not just scope
, emphasis, or omission."
  }
 ],
 "explanation": [
  {
```

```
   "factor": "study_period" | "population_or_cohort" | "endpoint_or_definition" | "
statistical_method_or_adjustment" | "interpretation_or_causal_attribution" | "
other_documented_factor" | "insufficient_information",
   "observation": "What the documents establish about a possible explanation for the
different conclusions or inability to compare.",
   "evidential_status": "documented_difference_causal_role_unproven" | "
plausible_explanation" | "insufficient_information",
   "human_quote": "Short contiguous verbatim passage, or null if absent.",
   "report_quote": "Short contiguous verbatim passage, or null if absent.",
   "causal_limit": "What cannot be established about why the conclusions differ from these
texts alone."
  }
 ],
 "coverage_or_emphasis_notes": "Omissions, scope shifts, secondary differences, or caveats
that should not themselves be counted as substantive disagreement.",
 "overall_evidence": {
  "human_quote": "Short contiguous verbatim passage supporting the human takeaway.",
  "report_quote": "Short contiguous verbatim passage supporting the report takeaway."
 },
 "rationale": "Two to four sentences justifying the overall decision."
}

For similar: difference_type=none, substantive_differences=[], explanation=[] (put non-
substantive distinctions in coverage_or_emphasis_notes).
For different: difference_type=empirical, interpretive, or both consistently with listed
differences; provide 1--3 substantive_differences and 1--3 explanation entries. If reasons
are unknown, use insufficient_information rather than invent them.
For not_comparable: difference_type=not_comparable, substantive_differences=[], and 1--3
explanation entries about scope or missing central analysis.
Every quotation must be an exact contiguous source substring after whitespace normalization
, preferably 10--35 words and at most 70 words. Retain Markdown formatting within quoted
text. Do not insert ellipses or join separated passages. Only explanation quotations may be
 null. For documented differences or plausible explanations, provide evidence from both
documents; for insufficient_information, null is allowed. Do not fill fields with
unsupported causal claims.
```

Prompt 2: Finding extraction

```
You are a meticulous oncology-epidemiology research assistant. You are given the full text
of a published study that analyzed the SEER cancer registry. Your job is to extract a bank
of ATOMIC VERIFIABLE CLAIMS: the study's concrete, data-derived findings and reproduction-
relevant study context, each stated so it could be independently checked from the raw data
or used to reproduce a data-derived result.

Rules for an atomic verifiable claim:
- It states ONE verifiable claim only. Split compound findings into separate claims.
- It may be numeric or non-numeric, but it must be empirically checkable from the study
data or necessary for reproducing such a check.
- If the paper reports concrete numbers for the claim, include them in "numbers" with units
 and context.
- If the claim is qualitative but data-derived, such as a distribution shape, ordering,
rank, threshold crossing, curve pattern, subgroup comparison, table pattern, or figure
pattern, keep "numbers" as an empty list and describe what should be checked in "
verification_target".
- Also extract operational study context when it is necessary to reproduce findings: cohort
 definitions, SEER variable/code definitions, inclusion/exclusion criteria, grouping rules,
 endpoint definitions, statistical methods, plotting methods, adjustment methods, and table
/figure construction rules.
- Preserve enough detail that another agent could decide what data subset, variables,
grouping, transformation, model, plot, or comparison is needed.
- Capture the verbatim sentence(s), table row, table note, figure caption, or methods text
that support the claim.
- Extract findings and reproducibility context from results, tables, figures, figure
captions, table notes, and methods sections.
- Skip background, motivation, citations of other studies, unsupported interpretation/
speculation, and purely clinical discussion not tied to a reproducible data operation.

Return a JSON object with a single key "claims" whose value is a LIST of objects. Each
object MUST use exactly these field names, and no others:
- "claim": string -- the one-sentence claim, written to be checkable.
- "evidence_type": one of "numeric", "categorical", "distributional", "trend_shape", "
ranking", "table_fact", "figure_pattern", "method_context", "other".
- "numbers": a LIST of objects, each with "value" (string), "unit" (string), and "context"
(string). Use an empty list if the claim is non-numeric.
- "verification_target": string -- what an analysis agent should compute, plot, compare,
inspect, or apply to verify this claim or use it during reproduction.
- "source_quote": string -- the verbatim supporting sentence(s), table row, table note,
figure caption, or methods text from the paper.
```

```
Use these exact keys. Do not rename fields. Return only the JSON object, no prose or
markdown fences.

Paper title: {{title}}

Full text:
{{full_text}}
```

Prompt 3: Atomic claim decomposition

```
You are splitting ONE grouped SEER reproduction claim into independently
testable scientific findings.

For numeric results, "atomic" means one substantive reported scalar. Related
numbers retain shared context but become separate atomic claims so each can be
reproduced and graded independently.

Splitting rules:
- Preserve every independently testable scientific result in the source claim.
- The curated source_claim.numbers array is the complete numeric target
  inventory. Every numeric child must correspond to an entry in that array.
  Never create a target from a number that appears only in source_quote or the
  full paper text.
- Split every substantive point value into its own atomic claim, including each
  baseline/follow-up value, each subgroup value, numerators, denominators,
  derived percentages, absolute differences, ratios, and other reported results.
- Example: "1,524 of 3,223 cases, or 47%" becomes three atomic claims: 1,524,
  3,223, and 47%. None is merely optional support.
- Example: an increase from 4.9 to 14.3 becomes one claim for 4.9 and one claim
  for 14.3. Preserve the year and baseline/follow-up role in each claim.
- Keep a confidence interval with its point estimate in one atomic claim. Never
  turn confidence-interval endpoints into standalone claims.
- Treat any parenthetical interval immediately following and enclosing a point
  estimate as optional uncertainty, even when source_claim.numbers calls it a
  "range" rather than a confidence interval. Example: `9.4 (8.9-9.9)` is one
  atomic claim for 9.4 with optional lower=8.9 and upper=9.9, not a second
  required range claim.
- Keep a meaningful range together as one atomic claim. Never turn range
  endpoints into standalone claims.
- Treat cohort definitions and analysis settings as context, not independent
  findings. Study years, age eligibility, registry counts, stage codes, and
  similar design numbers belong in required_analysis_assumptions unless the
  grouped claim explicitly presents that item as the substantive result.
- Split genuinely independent outcomes, subgroups, tumor types, or conclusions
  when each can stand alone scientifically.
- Create a qualitative direction or comparison claim only when that conclusion
  is independently testable and not redundant with the numeric child claims.
- Do not invent facts, precision, cohorts, units, or conclusions.
- Keep enough cohort, outcome, subgroup, geography, and time context for each atomic claim
to stand alone.
- Use the full paper to resolve context needed to make the exact result
  independently reproducible, but include only cohort and analysis details that
  apply to that result; do not automatically propagate broad paper-level
  restrictions into every atomic claim.
- A numeric atomic answer normally contains exactly one required component and
  exactly one substantive number in answer.value. Do not include contextual
  design numbers or other substantive results in answer.value.
- A genuinely range-valued result is the sole exception: keep its lower and
  upper endpoints together as two required components with roles "range_lower"
  and "range_upper". Set range_semantics="reported_interval" when the paper
  reports both endpoints as the result and both must be reproduced. Set
  range_semantics="acceptable_interval" when the range is a criterion and any
  scalar inside it satisfies the result. Do not use this exception for
  before/after or group pairs. Otherwise set range_semantics=null.
- Example: "the IRR declined to 4-5 at the oldest ages" is an
  acceptable_interval. A computed oldest-age IRR of 4.814 satisfies it; the
  agent need not manufacture or reproduce endpoints 4 and 5.
- Every required substantive component uses role "primary" except the two
  endpoints of a genuinely range-valued result.
- Preserve the numeric relation for every component. Use relation "eq" for a
  point estimate or an endpoint that the agent must reproduce, "lt" for
  "less than" or "below", "lte" for "at most" or "not exceeding", "gt" for
  "more than" or "above", and "gte" for "at least" or "no less than".
  Never discard an inequality or turn a lower/upper bound into an equality.
- Relation and comparator are separate: relation describes which values satisfy
  the finding, while comparator describes exact versus tolerance-based numeric
  matching for equality targets.
```

```
- Use comparator "relative_numeric" for approximate estimates, percentages,
  rates, ratios, and confidence limits. Use "exact_numeric" for exact counts or
  genuinely exact result parameters.
- Every required numeric component must include tolerance. Use
  {"kind":"relative","reproduced":0.05,"close":0.10} for estimates, rates,
  percentages, ratios, APCs, p-values, and counts. Use an absolute tolerance
  appropriate to the paper's precision for years, ages, timing, and targets at
  or near zero; for example, an approximate turning year reported to the nearest
  year normally uses {"kind":"absolute","reproduced":1,"close":2}. Use
  {"kind":"exact","reproduced":0,"close":0} only when exact identity is
  scientifically required.
- Set reported_decimal_places to the number of decimal places visibly reported
  for an equality target, so an unrounded reproduction that rounds to the paper's
  displayed value can match. Set it to null for inequalities and values whose
  displayed precision is not meaningful. Do not use this field to make vague
  words such as "about" artificially permissive.
- Use one canonical representation for changes and keep claim, label, value,
  and component consistent. "Decreased by 5%" and "magnitude of the decline"
  require the positive magnitude 5. "Increased by 5%" requires positive 5.
  "APC was -5%" or "signed APC" requires signed -5. Never pair change-magnitude
  wording with a negative target. Preserve threshold relations on the magnitude:
  "the magnitude of the decline was less than 1%" stores positive 1 with
  relation="lt".
- Keep confidence or uncertainty bounds with their point estimate in
  answer.uncertainty, not as separate atomic claims and not in components.
  uncertainty contains kind, level, lower, and upper. Use kind
  "interquartile_range" for an IQR. Each bound uses the same fields as a
  component but must have required=false. A correct point estimate can therefore
  reproduce the finding even when its uncertainty is not reported.
- Use answer_type "continuous_numeric" when all required result values are
  percentages, rates, APCs, p-values, ratios, estimates, confidence limits, or
  other approximate numeric values.
- Use answer_type "exact_numeric" only when the substantive result is a fixed
  numeric parameter or meaningful exact range.
- Use answer_type "count" when all required result values are exact counts.
- Use answer_type "categorical" for exact named categories or labels.
- Use answer_type "qualitative" for directions, rankings, comparisons, and patterns
requiring semantic grading.
- Copy or closely preserve the source quote that supports each atomic claim.
- Populate required_analysis_assumptions with the answer-safe protocol needed
  to compute this exact result. This setup is shown to the QA agent separately
  from the question, so it may be more specific than the source sentence.
- In required_analysis_assumptions.cohort, preserve every applicable registry,
  diagnosis-year, sex, race, stage, histology, behavior, primary-sequence,
  reporting-source, and eligibility restriction. Always state applicable age
  bounds explicitly and preserve inclusive semantics, for example "Include
  women age >=40 years" or "Restrict to ages 45-84 years, inclusive".
- In required_analysis_assumptions.coding, record the paper's exact variable,
  recode, code system and edition, code list, precedence rule, missing-value
  handling, and exclusion logic when stated.
- In required_analysis_assumptions.denominator_and_standardization, record the
  denominator population, rate scale, standard population, age bins, weight
  handling, and whether weights are renormalized after an age restriction.
- In required_analysis_assumptions.temporal_data, record the data release or
  vintage, follow-up cutoff, calendar grouping, and era-specific field mapping.
- In required_analysis_assumptions.statistical_model, record aggregation,
  smoothing, regression, joinpoint, survival, forecasting, significance, and
  model-selection settings needed for the target when the paper states them.
- Do not invent a protocol detail. If a necessary choice is not specified in
  the paper, add a concise statement in the relevant category beginning with
  "Not specified by the source:" so the ambiguity remains traceable.
- Neither required_analysis_assumptions nor agent_methodology_context may
  reveal the target answer, point estimate, comparison conclusion, or trend.
  Answer-bearing text belongs in evaluator_evidence.

Return only JSON with exactly one top-level key, "atomic_claims". Each item must contain
exactly:
- "claim"
- "evidence_type"
- "answer": {"value", "unit", "label", "answer_type", "components", "uncertainty", "
range_semantics"}
- "verification_target"
- "source_quote"
- "required_analysis_assumptions": {"cohort", "coding", "denominator_and_standardization",
"temporal_data", "statistical_model"}
- "agent_methodology_context"
- "evaluator_evidence"

Each required numeric component must contain exactly "value", "unit", "label",
"role", "relation", "comparator", "required", "reported_decimal_places", and
"tolerance". tolerance contains exactly "kind", "reproduced", and "close".
```

```
Optional uncertainty components use the same fields but may set tolerance=null.
Relation must be one of "eq", "lt", "lte", "gt", or "gte".

For categorical or qualitative answers, set components=[], uncertainty=null,
and range_semantics=null.

Example estimate with confidence interval:
{"value":"2.9 (95% CI 2.7-3.1)","unit":"relative rate","label":"relative rate","answer_type
":"continuous_numeric","components":[{"value":"2.9","unit":"relative rate","label":"point
estimate","role":"primary","relation":"eq","comparator":"relative_numeric","required":true
,"reported_decimal_places":1,"tolerance":{"kind":"relative","reproduced":0.05,"close
":0.10}}],"uncertainty":{"kind":"confidence_interval","level":"95%","lower":{"value
":"2.7","unit":"relative rate","label":"lower confidence limit","role":"range_lower","
relation":"eq","comparator":"relative_numeric","required":false,"reported_decimal_places
":1,"tolerance":null},"upper":{"value":"3.1","unit":"relative rate","label":"upper
confidence limit","role":"range_upper","relation":"eq","comparator":"relative_numeric","
required":false,"reported_decimal_places":1,"tolerance":null}},"range_semantics":null}

Example split for a before/after finding (two items in atomic_claims):
{"value":"4.9","unit":"per 100,000","label":"1975 baseline incidence","answer_type":"
continuous_numeric","components":[{"value":"4.9","unit":"per 100,000","label":"1975
baseline incidence","role":"primary","relation":"eq","comparator":"relative_numeric","
required":true,"reported_decimal_places":1,"tolerance":{"kind":"relative","reproduced
":0.05,"close":0.10}}],"uncertainty":null,"range_semantics":null}
{"value":"14.3","unit":"per 100,000","label":"2009 follow-up incidence","answer_type":"
continuous_numeric","components":[{"value":"14.3","unit":"per 100,000","label":"2009 follow
-up incidence","role":"primary","relation":"eq","comparator":"relative_numeric","required":
true,"reported_decimal_places":1,"tolerance":{"kind":"relative","reproduced":0.05,"close
":0.10}}],"uncertainty":null,"range_semantics":null}

Example lower-bound finding, "the IRR reached at least 0.7":
{"value":"at least 0.7","unit":"IRR","label":"lower-bound IRR","answer_type":"
continuous_numeric","components":[{"value":"0.7","unit":"IRR","label":"lower-bound IRR","
role":"primary","relation":"gte","comparator":"relative_numeric","required":true,"
reported_decimal_places":null,"tolerance":{"kind":"relative","reproduced":0.05,"close
":0.10}}],"uncertainty":null,"range_semantics":null}

Example upper-bound finding, "the percentage did not exceed 9%":
{"value":"not exceeding 9","unit":"%","label":"upper-bound percentage","answer_type":"
continuous_numeric","components":[{"value":"9","unit":"%","label":"upper-bound percentage
","role":"primary","relation":"lte","comparator":"relative_numeric","required":true,"
reported_decimal_places":null,"tolerance":{"kind":"relative","reproduced":0.05,"close
":0.10}}],"uncertainty":null,"range_semantics":null}

Worked example:
Source finding: "Overall, the age-adjusted CRC incidence rates significantly
decreased between 1975 and 2010 (APC -0.92; 95% CI -1.14 to -0.70, P<0.001)."
Better atomic claim (with this paper's context): "Among histologically confirmed colon or
rectal cancers
diagnosed in SEER 9 from 1975 through 2010, excluding nursing-home, autopsy, and
death-certificate reports, the age-adjusted incidence rate decreased by 0.92%
per year (95% CI -1.14% to -0.70%; two-sided P<0.001)."
Because this claim asks how much incidence decreased, use positive 0.92 as the
sole required answer component and label it "magnitude of annual incidence
decline". Store -1.14 and -0.70 as optional confidence bounds because those are
signed APC limits, and do not create a separate p-value claim. If the claim were
instead worded "the signed APC was -0.92%", preserve -0.92 as the target.

Paper metadata:
{{paper_metadata}}

Grouped source claim:
{{source_claim}}

Full paper text:
{{paper_context}}
```

Prompt 4: Reproduction execution

```
# Task: reproduce one published finding from the SEER 9 data

You are given direct query access to the SEER 9 cancer-registry table on a
SQL warehouse. Your job is to **independently reproduce the finding
below** by analyzing the data yourself (SQL to pull it, then any computation you
like), then report whether your computed result or observed pattern matches it.

## Temporal constraint (important)
The finding comes from a study published in **{{publication_year}}**. To make this a fair
```

```
reproduction of what that study could have done, restrict yourself to data and
resources that existed **on or before {{publication_year}}**:
- Do not use methods, software versions, or published results that postdate
  {{publication_year}}. The only data-release exceptions are the APPROVED staged population
  denominators and SEER*Explorer aggregate tables described below. Use those
  staged resources regardless of their packaging vintage, restrict their rows to
  the study's years and cohort, and do not go looking for an older vintage.
The SEER 9 case data itself is appropriate to use as provided.

## Do NOT look up the source (independence requirement)
This reproduction may use the provided source paper text for methodological
context, but the numbers must still be computed independently from the SEER 9
data. Therefore:
- You may read `paper_context.txt` to understand cohort definitions, exclusions,
  coding choices, statistical methods, tables/figure captions, and other context
  needed to reproduce the target claim.
- Do not search for, open, or fetch the paper, its abstract, or secondary pages
  from the web -- e.g. PubMed, PubMed Central (ncbi.nlm.nih.gov / pmc), journal
  sites, ResearchGate, or any page quoting the published numbers. Use the staged
  `paper_context.txt` copy only.
- Use the STAGED population tables for denominators (see "Population denominators"
  below) -- do NOT fetch population data from the web. The only acceptable
  web/reference use is generic, non-paper methodology documentation (e.g. how
  age-adjustment / APC works).
- The target claim below is given ONLY so you can state whether you matched or
  verified it. Treat any target numbers as a checksum -- do NOT copy results out
  of `paper_context.txt` or reverse-engineer your cohort/method to land on them.
  Use the paper for methods/context, compute or inspect the result yourself, then
  compare.

## The finding to reproduce
{{finding_json}}

## Paper context
The full source paper text is available in `paper_context.txt`. Use it as
context for the study's cohort, variable definitions, exclusions, and statistical
methods. The final reproduced number must come from your own data analysis.

## Local SEER manuals and documentation
Official NCI/SEER documentation is available under `manuals/`.
Start with `manuals/README.md`, which maps each local file to its source URL and
summarizes the contents. Useful paths include:
- `manuals/seerstat_nov2025/`: SEER*Stat variable dictionary and Research /
  Research Plus data description.
- `manuals/population/`: population denominator dictionary, modifications,
  single-year-age methods, hurricane-adjustment notes, and standard-population
  references.
- `manuals/coding_manuals/`: SEER Program Coding and Staging Manuals plus
  county, state, race, and reportability appendices.
- `manuals/variable_recodes/`: site recodes, stage variables, cause-of-death
  recodes, cause-specific death classification, race/ethnicity, months survived,
  and tumor-size recodes.
- `manuals/registry/`: SEER registry lists, groupings, and population
  characteristics.

Prefer these local manuals over web search for SEER documentation. You can use
`rg` and `find` to locate HTML/README content; for PDFs, use `pdftotext`, e.g.
`pdftotext manuals/seerstat_nov2025/TextData.FileDescription-nov2025.pdf - | rg -i "summary
 stage"`.
For the XLSX variable dictionary, use Python/pandas/openpyxl if the PDF or HTML
copy is not enough.

## Official SEER*Explorer aggregate tables
The warehouse also contains 34 staged tables from the official November 2024
SEER*Explorer archive. Their fully qualified names and columns are listed in
`schema.txt`; all names begin with `{{catalog}}.{{schema}}.seer_explorer_`.
These tables provide published aggregate incidence, mortality, survival,
prevalence, lifetime-risk, rural/urban, and preliminary-estimate data.

Read `manuals/seer_explorer_footnotes.md` before using an Explorer table. It
records data sources, age-adjustment and trend methodology, coding caveats, and
tab-specific qualifications. These are approved staged data resources even
though the archive packaging is a current release. Restrict queries to the
study's years, population, site, sex, race/ethnicity, age, and stage definitions,
and state clearly when an Explorer aggregate rather than the case-level table
supports the result.

## How to get the data
Read the SEER 9 table with the provided tool:

    python seer_sql.py "SELECT ... FROM {{case_table}} WHERE ..."
```

```
- See `schema.txt` for all column names and notes on the all-STRING typing and
  missing-value sentinels.
- The table is `{{case_table}}`.

## Population denominators -- use ONLY the staged tables
The SEER-9 population denominator tables in the database (described in
`schema.txt`, `{{catalog}}.{{schema}}.seer_pop_*`) are the APPROVED, authoritative
denominators for this task. They cover **1969-2024** with one row per
year x county x age x sex x race, so restrict to the years you need with a
`WHERE year BETWEEN ...` clause.
- Do NOT fetch external population files (SEER popdata, Census, NBER, etc.) over
  the web or in your own code -- use the staged tables as-is.
- These tables are a current-release vintage. The small population-estimate
  revision vs. the vintage the original study used is well within tolerance and
  is NOT worth pursuing -- do not hunt for an older-vintage file.
- Restrict the population to the SEER-9 counties (per the FIPS map in
  `schema.txt`) so the denominator matches the case cohort.

## How to compute -- work however you like
You are NOT limited to SQL. Pull whatever data you need with `seer_sql.py`, then
analyze it however is most appropriate:
- numpy, scipy, pandas, and statsmodels are PRE-INSTALLED -- just `import` them
  (no pip needed, and network installs will fail). Use them to save intermediate
  CSVs and fit regressions (age-adjustment, trend/APC models).
- There is no NCI Joinpoint binary here; implement joinpoint-style APC as a
  segmented / piecewise log-linear regression with statsmodels (with its standard
  errors / CIs) rather than a hand-rolled fit.
- Create as many working files in this directory as you want; you have a full
  scratch workspace here.
- You can also choose to just stick with SQL.

## Ground rules
- **Read-only on the database only.** The SEER table is shared and must not be
  modified: no INSERT/UPDATE/DELETE, DROP, CREATE/ALTER TABLE, or new tables/views
  -- issue **SELECT queries only** against it. This is the one hard restriction.
- Everything else (local files, scripts, packages) is fair game.

## What to deliver
Write your final report to a file named exactly `report.md` in this directory.
It must contain:
1. How you computed it: the SQL you pulled, plus any Python/analysis you ran. Just put all
code under code blocks inside the markdown file.
2. The numbers, pattern, figure/table property, or context item you computed,
   inspected, or applied.
3. A clear verdict: does your computation reproduce the finding (and how closely)?
4. If it does not match, your best explanation why (cohort definition, coding,
   age-adjustment standard, SEER 9 vs other registry coverage, etc.).

Only `report.md` is collected after the run; scratch files you create elsewhere
are discarded.
```

Prompt 5: Atomic reproduction grading

```
You are grading whether a data-analysis agent
reproduced EACH atomic result derived from one grouped SEER finding.

The report was originally produced for the grouped finding. Inspect every
atomic target independently. A value or conclusion for one target must not
affect any other target.

Your job is evidence extraction and method assessment, not numeric grading:
- answer_status is "reported" when the report gives the target result,
  "not_reported" when it does not, and "unclear" when the evidence is ambiguous.
- method_status is "valid" when the reported result was produced with a sound
  method for this target, "invalid" for a materially wrong cohort, measure,
  denominator, grouping, or calculation, and "unclear" when the report lacks
  enough methodological detail.
- Treat required_analysis_assumptions as part of the target protocol when
  assessing method_status. The agent report does not need to repeat every
  assumption verbatim, but its computation must be compatible with applicable
  cohort bounds, coding rules, denominator and standardization conventions,
  temporal data definitions, and statistical-model settings. A conflicting
  assumption is method_status "invalid"; insufficient evidence is "unclear".
- if_cheating is true only when the report indicates that the agent obtained
  the target result by recalling it, copying it from the source paper, or
  searching online for the reported answer instead of computing it from the
  provided data. Looking up documentation, variable definitions, or coding
```

```
  guidance is allowed when the agent then performs the computation itself.
  Do not infer cheating merely because a computed value matches the target.
  When the report does not establish a credible computation, use
  method_status "unclear" or "invalid" as appropriate even if
  if_cheating is false.
- For numeric targets, return one object per corresponding required result in
  computed_components. Each object has value, relation, and unit. Use the
  report's unrounded computed value whenever it is available, in target order
  and target units. Most targets require one number. A reported interval requires
  two endpoints; an acceptable interval requires the one computed scalar being
  tested. Never duplicate one scalar to manufacture two endpoints. Also put a
  compact legacy rendering of these same values in computed_value. Ignore
  optional confidence bounds. Set semantic_verdict to "not_applicable". Do not
  calculate relative error, apply a tolerance, or assign a final verdict.
- Normalize change direction to the representation requested by the atomic
  target. If the target asks for the magnitude of a decline or says "decreased
  by", convert a report's signed APC of -1.09 to the positive magnitude 1.09.
  If the target asks for a signed APC, preserve -1.09. Do not otherwise change
  signs.
- For a lower- or upper-bound target, extract the report's actual computed value,
  not the target boundary. Example: for target ">5", return "5.51" when the
  report computed 5.51. For target "P<0.0001", return "2.94e-26" when that is
  the computed P value. If the report supplies only a bound, preserve its
  relation in computed_components and operator in computed_value, such as
  "<0.0001". Never replace a reported value with the reference threshold.
- Preserve the unit and scale actually computed. For example, distinguish a
  percentage from a proportion and a rate per 100,000 from a raw count. Use an
  empty unit only when the report truly does not state or establish one.
- For qualitative or categorical targets, set semantic_verdict to
  "equivalent", "approximately_equivalent", "conflicting", or "unclear" by
  comparing the report's conclusion with the target. Use "not_applicable" only
  for numeric targets.

Return ONLY one JSON object with key "grades". "grades" must contain exactly
one object for every supplied atomic_claim_id, with no missing or extra IDs.
Each grade object must contain exactly these keys: atomic_claim_id,
answer_status, computed_components, computed_value, method_status, if_cheating,
semantic_verdict, key_caveat, and rationale. computed_components must be [] for
non-numeric targets. Each numeric computed component must have exactly value,
relation, and unit, where relation is eq, lt, lte, gt, or gte. if_cheating must
be a JSON boolean. Use only the enum values specified above.

## ATOMIC targets and grading policies
{{targets}}

## Agent REPORT
{{report}}
```

Prompt 6: Reproduction failure classification

```
You are analyzing failed atomic targets from a scientific reproduction agent that queried
staged NCI SEER data. Classify why each target was not reproduced.

Use the reproduction report and grader records as evidence. The grader record contains the
target, extracted computed value, and prior rationale, but you must distinguish the
underlying cause rather than restating the numeric mismatch.

Assign exactly one primary_issue per atomic target:
- data_unavailable: required records, variables, geography, endpoint, years, or historical
schema are absent from the staged data.
- target_under_specified: the paper's exact operational definition, model, test, or context
 cannot be uniquely inferred from the target and available documentation.
- agent_omission: the target appears computable, but the agent did not attempt it or failed
 to report the result.
- cohort_or_coding_error: the agent used the wrong population filter, disease/histology
definition, stage, treatment, or tumor-size coding.
- denominator_or_standardization_error: the agent used the wrong denominator, rate scale,
age standard, weighting, or change formula.
- statistical_method_error: the agent used an unsuitable test, regression, joinpoint/time
segmentation, aggregation, or other statistical procedure.
- survival_or_endpoint_error: the agent used the wrong mortality/survival endpoint,
censoring, event definition, or follow-up.
- valid_alternative_estimate: the agent performed a defensible computation, but a data-
vintage, extract, small-sample, or reasonable operationalization difference produced a
materially different estimate.
- qualitative_result_conflict: the computed direction, ranking, or pattern directly
conflicts with the target and no narrower cause is supported.
```

```
- grading_artifact: the substantive result should likely count, but atomicization, parsing,
 rounding, inequality, or tolerance policy caused rejection.
- contamination_or_lookup: the answer was copied, recalled, or obtained online instead of
being computed from staged data.
- insufficient_evidence: evidence is inadequate to choose another category.

issue_codes are narrower contributing diagnoses. Put the code that best supports
primary_issue first. Multiple codes are allowed only when independently supported.

Use only these exact issue_codes strings:
missing_records, missing_variable, missing_geographic_granularity,
missing_external_endpoint, temporal_coverage_or_schema, paper_method_not_identifiable,
claim_context_incomplete, not_attempted, result_not_reported, wrong_cohort_filter,
wrong_disease_or_histology_coding, wrong_stage_treatment_or_size_coding, wrong_denominator,
 wrong_age_standardization, wrong_rate_or_change_calculation, wrong_statistical_test,
wrong_model_or_time_segmentation, small_sample_instability, wrong_survival_endpoint,
wrong_censoring_or_followup, data_vintage_or_extract_difference,
defensible_operationalization_difference, qualitative_direction_or_ranking_conflict,
numeric_tolerance_or_rounding, atomic_target_or_reference_issue, copied_or_recalled_answer,
 tool_or_query_failure, cause_unclear.

Use only these exact responsibility strings: benchmark_data, benchmark_specification, agent
, evaluator, scientific_variation, unclear.

Use only these exact computability strings: computable_from_staged_data,
partially_computable, not_computable_from_staged_data, unclear.

Use only the strings high, medium, or low for confidence. The evidence field must be one
string, not a list.

Important distinctions:
- Missing data is not an agent error when the report correctly analyzes and documents the
absence.
- A value outside tolerance is not automatically an agent error. Use
valid_alternative_estimate when the method is defensible and comparable.
- Use grading_artifact for values that agree after the benchmark's intended rounding/
inequality semantics or for a defective atomic reference.
- Qualitative grading is intentionally binary. A qualitative grade of close_to_reproduced
or approximately_equivalent is therefore an effective failure, not automatically a grading
artifact. Diagnose the missing, weakened, or conflicting semantic content. Use
grading_artifact only if the report actually establishes the complete target and the judge
or reference rejected it incorrectly.
- Use target_under_specified only when a hidden paper-specific choice prevents unique
reproduction, not merely because the agent chose poorly.
- Use agent_omission when data and method appear available but no result was attempted or
reported.
- Documentation or web lookup is allowed when it supports a real computation.
contamination_or_lookup requires that the reported result itself was not computed.
- Keep diagnosis and evidence specific to this case. Do not invent unavailable facts.

Return JSON with one classifications item for every input atomic_claim_id and no others. Do
 not create any enum values beyond those listed above. Each item must contain:
atomic_claim_id, primary_issue, issue_codes, responsibility, computability, diagnosis,
evidence, recommended_action, confidence.

FAILED TARGETS:
{{failure_rows_json}}

REPRODUCTION REPORT:
{{report}}
```

Prompt 7: Scientific frame and eligible claims

```
You construct an outcome-blind scientific frame for one SEER research question. The
claim_reproduction_index contains only original paper insights whose required atomic claims
 were all strictly reproduced. Extract headline and supporting claims only from this
supplied index; do not extract additional result claims directly from the paper. Copy each
selected entry's source_insight_id exactly into the corresponding output claim.

Then enumerate scientifically material analytical assumptions from the original paper plus
ontology gaps suggested by the filtered reproduction_index. The reproduction_index contains
 execution evidence only for the same fully reproduced insights eligible for this analysis.
 Do not use, infer, or predict sensitivity results. Do not manufacture candidates to hit a
quota.

Candidate IDs must be H01, H02, ... in importance-neutral document order. Each candidate is
 one underlying decision, not a collection of loosely related settings. Include assumptions
```

```
 that are necessary but unspecified. Link every candidate to at least one extracted full
claim. Cover every ontology family as covered, unresolved, or genuinely not applicable.

Evidence quotes must be exact contiguous substrings from original_paper or serialized
reproduction_index. The claim_reproduction_index establishes claim identity and eligibility
 but is not an evidence-quote source. Use reproduction_index only for what its metadata and
 claim text actually establish; it is reconstruction evidence, not author execution. Return
 only the JSON object required by the schema.
```

Prompt 8: Candidate choices in generated reports

```
Extract scientifically material analytical assumptions from one generated report and its
own original query log. Use the supplied canonical paper claims only for linkage; do not
force the report to address every claim. Do not use or predict sensitivity outcomes.

Candidate IDs must use candidate_prefix followed by sequential two-digit numbers. One
candidate must represent one underlying decision. Distinguish explicit report statements,
execution-observed settings, necessary but unspecified choices, and genuinely unknown
decisions. Do not treat absent analysis as an assumption. Evidence quotes must be exact
contiguous substrings of report or query_log. Return only the JSON object required by the
schema.
```

Prompt 9: Candidate extraction repair

```
Repair one generated-report candidate set using the supplied validation error. Preserve the
 artifact identity, candidate order, candidate IDs, scientific decisions, and all already
valid evidence. Change only evidence fields needed to make every quote an exact contiguous
substring of the named report or query log. Do not import wording or decisions from another
 source. Return only the complete repaired JSON object required by the schema.
```

Prompt 10: Shared analytical choice selection

```
Create one shared canonical assumption panel for the paper from the candidate pool. Every
canonical item must be a neutral scientific decision axis, not an assertion that one source
-specific value is the common baseline. Source-specific values, implementations, and
disagreements are resolved later in source mapping. Merge candidates that express the same
underlying scientific decision across Human, Sol, and Opus evidence even when their chosen
values differ. Do not merge merely correlated decisions and do not split incidental
implementation details unless changing them independently defines a different meaningful
sensitivity question.

A single source candidate may imperfectly mention more than one decision. Do not broaden a
canonical item merely to absorb all of that candidate's wording. Attach the candidate to
its primary decision axis, preserve nearby decisions as separate canonical items when
scientifically warranted, and rely on the later source-mapping stage to inspect the full
source evidence. Fixed, data-selected, and differently bounded values may share one
canonical axis when they are alternative settings of the same scientific choice.

Rank prospectively using only the supplied criteria. Candidate frequency, report verbosity,
 source identity, and source omissions are not importance evidence. No empirical outcomes
are available. Select at most panel_ceiling assumptions and return fewer when remaining
candidates are redundant or low value. Preserve meaningful family diversity near the
selection boundary.

Canonical names and definitions must state what decision is being made and its scope
without selecting one source's value. Canonical IDs must be P<paper_id>-C01, P<paper_id>-
C02, ... in selected rank order. candidate_refs use <pool key>__<candidate_id>, for example
 human_paper__H01 or sol_p22_open__S03. Each candidate reference may appear in at most one
selected assumption. Score totals must equal the sum of component scores. Return only the
JSON object required by the schema.
```

Prompt 11: Analytical choice review

```
Review the proposed shared canonical panel without using empirical outcomes. Check that it
captures the highest-priority nonredundant decisions, uses neutral decision axes, merges
equivalent scientific choices, preserves distinctions between different sensitivity
questions, follows the score ranges, avoids source-frequency bias, and has reasonable
family diversity.
```

```
Do not reject a canonical item merely because sources chose conflicting values or
implementations; those differences belong in source mapping. Fixed, data-selected, and
differently bounded values can be valid members of one axis when switching among them is
one coherent sensitivity question. Conversely, reject an item when its components can be
varied independently to answer meaningfully different scientific questions. A non-atomic
source candidate may be attached to its primary axis without forcing every decision
mentioned by that candidate into the same canonical item.

Review every canonical assumption in order. Approve only if no scientifically material
repair remains; optional wording refinements or lower-ranked alternatives are not required
repairs. Return only the JSON object required by the schema.
```

Prompt 12: Analytical choice repair

```
Repair the draft canonical panel exactly once using the supplied review. The repaired panel
 must remain outcome-blind and use only the original claims and candidate pool. Every
repaired item must be a neutral decision axis; source-specific values and disagreements
belong in later source mappings. Do not overmerge distinct decisions to absorb every part
of a non-atomic source candidate, and do not split alternative values that answer the same
coherent sensitivity question. Fix required omissions, redundancy, merging, scoring, or
diversity issues without manufacturing low-value assumptions. Reassign sequential canonical
 IDs in final selected rank order and keep at most panel_ceiling assumptions. Return only
the JSON object required by the schema.
```

Prompt 13: Final analytical choice repair

```
Perform the final bounded repair of the shared canonical panel using the supplied review.
The repaired panel must remain outcome-blind and use only the original claims and candidate
 pool. Every item must be a neutral scientific decision axis; source-specific values and
disagreements belong in later source mappings.

Resolve every scientifically material issue in the review. Do not overmerge independently
variable decisions, but do not split fixed, data-selected, or differently bounded values
when they answer the same coherent sensitivity question. A non-atomic source candidate may
be attached to its primary axis without forcing all decisions mentioned by that candidate
into one item. Rerank prospectively, displace lower-priority items when necessary, reassign
 sequential canonical IDs, and keep at most panel_ceiling assumptions. Return only the JSON
 object required by the schema.
```

Prompt 14: Final analytical choice review

```
Perform the final outcome-blind specification review of the shared canonical panel. Check
that the panel captures the highest-priority nonredundant decisions, uses neutral decision
axes, preserves distinctions between independently variable scientific questions, follows
the score ranges, avoids source-frequency bias, and has reasonable family diversity.

Do not reject an item merely because sources chose conflicting values or implementations;
those differences belong in source mapping. Fixed, data-selected, and differently bounded
values can share one axis when switching among them is one coherent sensitivity question. A
 non-atomic source candidate may be attached to its primary axis without forcing every
decision it mentions into the same item.

Review every canonical assumption in order. Approve only if no scientifically material
repair remains. Optional wording refinements and lower-ranked candidate substitutions are
not required repairs. Return only the JSON object required by the schema.
```

Prompt 15: Analytical choice resolution

```
Produce the final outcome-blind canonical panel by resolving the supplied review as a
binding checklist, not as optional advice. This is a fresh resolution stage after prior
bounded repairs failed.

For every entry in `review.required_repairs`, `review.missing_high_priority_assumptions`, `
review.redundancy_issues`, `review.diversity_issues`, and every rejected `
assumption_reviews` item, make a concrete corresponding change in the returned panel. Do
not return an unchanged panel. If a repair says to add or replace an axis, create that
separate neutral scientific decision axis and attach the specified candidate evidence; do
not hide it inside another independently variable decision. If the panel is already at 20
items, remove or replace the lowest-priority selected item needed to satisfy the repair. If
```

```
 a repair moves or splits candidate support, update candidate_refs, merge_rationale,
distinct_from, exclusions, ranking, scores, and diversity_rationale consistently.

Before returning, internally analyze the result as if each required repair were a unit test
:

1. Every required missing axis is present as its own canonical assumption when requested.
2. Every requested replacement actually removes the rejected item or recasts it exactly as
directed.
3. Candidate references support the primary axis to which they are attached.
4. Independently variable population, measurement, time, endpoint, model, inference,
subgroup, and interpretation decisions are not overmerged.
5. The panel contains no more than `panel_ceiling` assumptions, IDs are sequential, scores
and selection rationales are prospective, and the diversity rationale describes the
returned panel rather than an earlier draft.
6. The panel remains outcome-blind and uses only the supplied claims and candidate pool.

Return only the canonical-panel JSON object required by the schema.
```

Prompt 16: Source-specific baseline mapping

```
Map one source artifact to every assumption in the frozen canonical panel, in panel order.
Mapping state and baseline provenance are separate judgments. An explicit narrative value
is not automatically a complete executable baseline. A missing denominator, definition, or
window that the analysis necessarily uses is implicit_unspecified, not not_applicable. Use
not_applicable only when the source makes no analysis or conclusion requiring the decision.
 Every not_applicable mapping must use baseline_state unavailable, empirical_feasibility
not_applicable, omission false, source_value not_applicable, and an empty evidence list.

For Human evidence, reproduction_index supports conditional reconstructability only; it is
not author execution. For generated reports, query_log is that artifact's own execution
evidence. Assess justification independently of observability. Evidence quotes must be
exact contiguous substrings of report, query_log, or serialized reproduction_index.
Evidence may be empty only for a genuinely not-applicable or unsupported implicit mapping,
with the limitation explained. Return only the JSON object required by the schema.
```

Prompt 17: Source mapping repair

```
Repair one source-to-panel mapping using the supplied validation error. Preserve the
artifact identity, canonical panel order, evidence-grounded scientific judgments, and all
already valid rows. Change only fields needed to satisfy the mapping contract or exact-
quote validation.

Required invariants:
- Every canonical assumption appears exactly once and in panel order.
- If mapping is not_applicable, baseline_state must be unavailable, empirical_feasibility
must be not_applicable, and omission must be false.
- If mapping is implicit_unspecified, omission must be true.
- Evidence quotes must be exact contiguous substrings of the named report, query_log, or
serialized reproduction_index.
- Human reproduction evidence supports at most conditional reconstructability; it is not
author execution.

Return only the complete repaired JSON object required by the schema.
```

Prompt 18: Shared alternative generation

```
Generate shared outcome-blind alternatives for the frozen canonical panel. Alternatives
attach to the canonical scientific decision, not to individual sources. Generate one
primary alternative by default and a second only when it represents a materially different
defensible direction. It is acceptable to generate none.

Each alternative must be scientifically defensible, sufficiently specified, linked to
claims, and either preserve the same question or define a bounded claim-support test.
Freeze dependent updates, feasibility requirements, executor family, and observable
consequence criteria before execution. Do not use or predict sensitivity outcomes. IDs must
 be <canonical_id>-ALT1 and optionally ALT2 in order. Return one assessment for every
canonical assumption in panel order and only the JSON required by the schema.
```

Prompt 19: Alternative generation repair

```
Repair the supplied shared-alternatives draft so it covers every canonical panel assumption
 exactly once and in the same order as canonical_panel. Preserve valid existing scientific
alternatives. Add the omitted assessments, using zero alternatives with a clear
no_alternative_reason when no bounded same-question alternative is defensible, or at most
alternative_ceiling alternatives when they are defensible. Alternatives remain shared
scientific definitions rather than source-specific inventions. Do not use or predict
empirical outcomes. Return only the complete corrected JSON object required by the schema.
```

Prompt 20: Prospective alternative review

```
Review every proposed shared alternative independently of empirical outcomes. Determine
whether its scientific justification, scope relation, specification, and in-principle SEER9
 feasibility support admission. A claim-support alternative may qualify interpretation but
cannot directly refute a different estimand. Do not invent replacement alternatives. Return
 one review per proposed alternative, using exact IDs, and only the JSON object required by
 the schema.
```

Prompt 21: Alternative review repair

```
Repair the proposed-alternative review using the supplied validation error. Preserve all
scientifically valid admission decisions and rationales from the draft. Return exactly one
review for every proposed alternative, in proposed order, using exact alternative IDs.
Remove duplicates, invented alternatives, and placeholder rows for assumptions with no
proposed alternative. Do not change the proposed alternatives or use empirical outcomes.
Return only the complete JSON object required by the schema.
```

Prompt 22: Execution planning

```
Create the cheap eligibility matrix and grouped execution plan for one frozen paper panel.
Decide every source-artifact × proposed-alternative pair. Respect source mapping, baseline
provenance, alternative admission, evidence availability, and applicability. Untested,
unavailable, or implicit choices are never stable.

Group executable comparisons into at most job_ceiling paper-family jobs. Prefer
deterministic parameterized execution and shared extracts. A job can serve multiple sources
 and alternatives when definitions and data dependencies overlap. Use fallback_agent only
when an admitted important comparison cannot be represented by a deterministic family. Non-
executable comparisons must have an empty job_id. Comparison IDs must be <artifact_id>__<
alternative_id>. Job IDs must be P<paper_id>-J01, P<paper_id>-J02, ... . Return only the
JSON object required by the schema.
```

Prompt 23: Execution plan repair

```
Repair the supplied draft execution plan so it exactly matches the frozen execution-plan
schema and constraints. Preserve the scientific alternatives, source-specific decisions,
comparison coverage, and validation intent. Decide every source-artifact × proposed-
alternative pair exactly once. Use no more than job_ceiling jobs by consolidating
compatible jobs that can share extracts or execution families; do not drop executable
comparisons merely to meet the cap. Keep non-executable comparisons jobless. Use comparison
 IDs <artifact_id>__<alternative_id> and sequential job IDs P<paper_id>-J01, P<paper_id>-
J02, ... . Return only the complete corrected JSON object required by the schema.
```

Prompt 24: Analysis execution

```
# Task: execute one frozen matched assumption analysis

You are the scientific execution component of a frozen SEER-9 assumption-analysis pipeline.
 You have received exactly one blinded source artifact. Execute every comparison whose
decision is `execute` in `execution_plan.json`. The canonical assumptions, alternatives,
linked claims, source mapping, and consequence criteria are frozen. You may not add, remove
, merge, reinterpret, or tune them after seeing results. Do not infer or speculate about
who produced the source artifact or whether it came from a publication or a model.

## Inputs
```

```
- `run_manifest.json`: exact jobs and comparison IDs that must be covered.
- `execution_plan.json`: grouped jobs, required fields, validation checks, and all source-alternative decisions.
- `paper_frame.json`: research question and frozen source claims.
- `canonical_panel_selected.json`: frozen canonical assumptions.
- `canonical_alternatives.json`: frozen alternatives and consequence criteria.
- `alternative_admission.json`: prospective admission judgments.
- `source_mapping.json`: the frozen baseline mapping for the single supplied source artifact.
- `source_evidence.json`: the source report and its available execution evidence.
- `supporting_evidence_manifest.json` and `supporting_evidence/`: additional reconstruction or triangulation evidence when available. This evidence is not proof that the source's baseline specification was executed exactly.
- `code_capsule_manifest.json` and `code_capsules/`: baseline implementation evidence for the single supplied artifact. `captured_workspace` is preserved executable work, `structured_trace_recovery` is identity-neutral structured tool-call evidence from the original execution, `transcript_recovery` is a legacy implementation recovered from transcript/query evidence, and `fresh_reconstruction` means no prior implementation survived.
- `schema.txt`, `manuals/`, `seer_sql.py`, and `operator_helpers.py`.
- `result_schema.json`: required output schema.

## Local SEER manuals and documentation

Official NCI/SEER documentation is staged in the execution environment under `manuals/`. Start with `manuals/README.md`, which maps each file to its source URL and summarizes its contents. Useful paths include:

- `manuals/seerstat_nov2025/`: SEER*Stat variable dictionary and Research / Research Plus data description.
- `manuals/population/`: population denominator dictionary, modifications, single-year-age methods, hurricane-adjustment notes, and standard-population references.
- `manuals/coding_manuals/`: SEER Program Coding and Staging Manuals plus county, state, race, and reportability appendices.
- `manuals/variable_recodes/`: site recodes, stage variables, cause-of-death recodes, cause-specific death classification, race/ethnicity, months survived, and tumor-size recodes.
- `manuals/registry/`: SEER registry lists, groupings, and population characteristics.

Prefer these staged official manuals over unstated conventions or memory. Use `rg`, `find`, and `pdftotext` to locate the exact definitions needed for each baseline and alternative, and cite the relevant manual paths in saved validation evidence.

## Official SEER*Explorer aggregate tables

The warehouse also contains 34 staged tables from the official November 2024 SEER*Explorer archive. Their names and columns are listed in `schema.txt`; all names begin with `seer.seer.seer_explorer_`. These tables provide published aggregate incidence, national mortality, survival, prevalence, lifetime-risk, rural/urban, and preliminary-estimate data. In particular, use the U.S. mortality tables when the research question requires calendar-year national vital-statistics mortality rather than mortality conditional on a SEER diagnosis.

Read `manuals/seer_explorer_footnotes.md` before using an Explorer table. It records data sources, age-adjustment and trend methodology, coding caveats, and tab-specific qualifications. These are approved staged data resources even though the archive packaging is a current release. Restrict queries to the study's years, population, site, sex, race/ethnicity, age, and stage definitions, and state clearly when an Explorer aggregate rather than the case-level table supports the result. Do not copy a published target result from source literature; independently select and analyze the applicable staged rows.

No prior sensitivity outcome, adjudication, or verdict is available or permitted. Do not search the web, inspect files outside `/work`, or instantiate another agent.

## Execution rules

1. Use `seer.seer.seer9` as the case backbone. Auxiliary population tables are allowed only as denominators.
2. Use only `seer_sql.py` for SQL. It is read-only, caches complete results, and records `query_log.jsonl`. Retrieve aggregate sufficient statistics whenever possible.
3. Implement all new or modified analysis under `analysis/`. Save executable Python/R/SQL code, intermediate checks, compact result tables, validation receipts, and unified diffs. Do not rely on narrative assertions alone.
4. Treat the supplied artifact as the only baseline in this workspace. Select one of its code capsules without attempting to identify or compare it with another source. Prefer a successful `captured_workspace` capsule, then `structured_trace_recovery`. Use legacy `transcript_recovery` only when neither is available for that estimand, and use `fresh_reconstruction` only when no implementation evidence survives.
5. Materialize one frozen baseline implementation per `source_artifact::job_id` and reuse it across every related comparison in that job. Do not independently reconstruct the same source/estimand for each alternative.
```

```
6. Before changing any assumption, run the selected baseline implementation unchanged.
Apply every job-level validation check, save the validation evidence under `analysis/`, and
 record `passed`, `failed`, or `unavailable`. A reproduction report or a matching published
 number is supporting evidence, not automatic baseline certification. A comparison cannot
be `complete` unless unchanged baseline validation passes.
7. Create the alternative by copying the validated baseline implementation and changing
only the frozen canonical decision and its listed dependent updates. Keep all other code,
filters, definitions, windows, estimators, and thresholds fixed. Save an exact unified diff
 from baseline to alternative.
8. Do not tune code, windows, definitions, model choices, or thresholds to reproduce a
reported number or to create a consequential result.
9. If baseline evidence, a required field, same-question comparability, or computation is
unavailable, return `inconclusive` or `unavailable`. Never call an unexecuted comparison
stable.
10. Execution outputs contain measurements only. Do not assign `direct_claim_change`, `
interpretive_qualification`, or `stable_under_test`; a separate adjudication stage applies
those labels.
11. Interpretation-family jobs must use a frozen deterministic rubric over the supplied
claims and empirical outputs. Save the rubric and its application under `analysis/`.

## Required output

Write `execution_bundle.json` conforming exactly to `result_schema.json`.

- Include every job in `run_manifest.json` exactly once and in order.
- Include every executable comparison assigned to that job exactly once and no others.
- For each comparison, provide `status`, structured `baseline`, structured `alternative`,
structured `metrics`, `evidence_files`, and `limitations`.
- For each comparison, provide `code_lineage` with the capsule origin and ID, the exact `
artifact_id::job_id` reuse key, SHA256 records for baseline files, baseline-validation
evidence, alternative files, and the exact unified baseline-to-alternative diff.
- Completed comparisons require nonempty baseline, alternative, and metrics objects.
- Completed comparisons also require a nonempty baseline implementation, passed baseline
validation with evidence, a nonempty alternative implementation, and a nonempty unified
diff.
- Inconclusive or unavailable comparisons require a specific limitation and saved
diagnostic evidence.
- Every evidence path and implementation path must begin with `analysis/`, exist, and be
nonempty.

Before finishing, validate the JSON locally against `result_schema.json` and verify exact
ID coverage against `run_manifest.json`.
```

Prompt 25: Consequence adjudication

```
Adjudicate the completed matched source--alternative comparisons using only the supplied
frozen claims, canonical assumptions, admitted alternatives, consequence criteria, and
deterministic family results. Do not invent analyses, alternatives, thresholds, claims, or
evidence.

Use exactly one outcome per comparison:
- `direct_claim_change`: the frozen criterion shows a source claim changes truth value,
direction, significance, or declared categorical conclusion.
- `interpretive_qualification`: the result materially narrows scope, robustness, or
evidentiary strength without directly changing the claim.
- `stable_under_test`: the completed admitted comparison does not meet the frozen
consequence criterion.
- `inconclusive`: execution or evidence cannot support a verdict.
- `unavailable`: execution established that required data, fields, baseline settings, or
source evidence are unavailable.

Apply the alternative's listed consequence criteria explicitly. A numerical difference
alone is not automatically consequential. A `claim_support` alternative ordinarily yields
an interpretive qualification rather than a direct claim change unless the frozen criterion
 explicitly determines the source claim's truth value. A runtime result whose status is `
unavailable` must remain `unavailable`; a runtime result whose status is `inconclusive`
must remain `inconclusive`. Never convert missing, failed, unavailable, or inconclusive
evidence into stability. Cite only supplied evidence-file paths. Return every supplied
comparison exactly once and only the JSON object required by the schema.
```

Prompt 26: Execution continuation

```
The previous turn stopped before producing /work/execution_bundle.json. Continue in the
same workspace and reuse all existing files under /work/analysis. Do not narrate another
plan and do not restart completed analysis. Finish every remaining frozen comparison, write
```

```
 /work/execution_bundle.json, validate it against /work/result_schema.json and the exact
IDs in /work/execution_plan.json, and do not finish until the required bundle exists with
exact comparison coverage.
```

Prompt 27: Execution finalization

```
STOP ANALYSIS AND FINALIZE NOW. Do not run more SQL, inspect more manuals or source
evidence, or write narrative reports. Reuse the analysis already present under /work/
analysis. Your first tool call must create /work/execution_bundle.json covering every exact
 comparison ID in /work/execution_plan.json. For any comparison whose evidence cannot be
completed from existing files, record it as unavailable with a precise limitation rather
than doing more research. Then validate the bundle against /work/result_schema.json and the
 frozen plan, repair only structural validation defects, and do not finish until /work/
execution_bundle.json exists and validates.
```

Prompt 28: Execution task

```
Read AGENTS.md and execute the complete frozen analysis for the single supplied source
artifact. Save execution_bundle.json and all analysis evidence exactly as instructed. Do
not infer the source identity, search the web, or launch other agents.
```

Prompt 29: Structured output repair

```
Return a corrected complete JSON object matching the supplied schema. Preserve supported
scientific content, fix the validation error, and do not add commentary. Validation error:
{{validation_error}}
```

Prompt 30: Coding agent instructions

```
You are a coding agent operating inside an isolated scientific analysis container. Use
run_shell to inspect files, write code, execute read-only analyses, and validate outputs.
Follow the staged instructions exactly. Do not inspect environment variables or paths
outside /work. Continue until the required output exists and validates.
```

Prompt 31: Coding agent continuation

```
The task is not complete: {{required_output}} is missing or empty. Continue using tools
until it exists and validates.
```

Prompt 32: One-shot analytical-choice analysis

```
# Consequential-assumption analysis

Analyze the completed research report in `report.md` for consequential analytical
assumptions.

A consequential analytical assumption is a choice in population, measurement, time window,
denominator, endpoint, model, inference, subgrouping, missing-data handling, or
interpretation for which a plausible and scientifically justifiable alternative can
materially change a substantive reported finding or conclusion.

Use all available evidence:

- the research question in `question.txt`;
- the completed report in `report.md`;
- the original report-generation SQL history in `original_query_log.jsonl`, when present;
- the surviving original-agent output files under `original_agent_evidence/`, when present;
- for published Human papers, the selected GPT-5.6 Sol / SEER-9 reproduction reports, SQL
logs, transcripts, and provenance under `reproduction_evidence/`;
- the source-specific baseline implementation manifest in `code_capsule_manifest.json` and
preserved or recovered implementation evidence under `code_capsules/`;
- the SEER schema in `schema.txt`;
- local official documentation under `manuals/`;
```

```
- live read-only SEER 9 access through `seer_sql.py`.

Treat reproduction evidence as an additional feasibility and triangulation signal. It is a
reconstruction of claims from the paper, not original author execution and not proof that
the paper's baseline specification was reproduced exactly. Prefer a successful `
captured_workspace` capsule, then `structured_trace_recovery`. If only legacy `
transcript_recovery` exists, explicitly identify the implementation as recovered; if no
implementation survives, explicitly identify any new baseline code as `fresh_reconstruction
`.

Independently inspect and, where feasible, empirically test plausible alternative choices.
First run and validate the selected baseline implementation unchanged. Then copy it and
change only the assumption being tested and its necessary dependent updates; keep all other
 computation fixed and save a unified diff. Reuse one baseline implementation for related
tests of the same estimand. Keep alternatives tied to the same research question or to
support for a claim actually made in the report. Do not merely list generic limitations.
Distinguish alternatives that change a finding or conclusion from alternatives that are
stable, inconclusive, infeasible, or not scientifically justified.

Do not search for the source paper or any hidden benchmark answer. No checklist of
assumptions is supplied; perform the analysis from first principles.

Write a self-contained natural-language analysis to `analysis.md`. For each important
assumption, explain the report's operative choice, the justifiable alternative, what
evidence or test you used, and the effect on the report's substantive findings or
conclusions. Include enough numerical or categorical detail for another reader to
understand the comparison. End with a concise summary of which assumptions were
consequential.
```

Prompt 33: Ordinal consequentiality grading

```
# Analytical-choice consequentiality --- 1--9 grading prompt v3

Version 3 adds a short rationale. The nine score anchors are unchanged.

This is a proposed ordinal scale, not a validated instrument. It grades scientific
consequence, not evidence quality.

## Input prerequisite

The calling workflow must supply the target document's substantive conclusions, baseline
and alternative choices, and interpretable results for both. Resolve missing, failed, or
fundamentally noncomparable analyses before invoking this grader. Missing evidence is not a
 score of 1. Evidence sufficiency is a prerequisite, not an additional output.

## Prompt

Assess how consequential a specified analytical choice is to a scientific document's
conclusions. Evaluate the baseline-to-alternative contrast using the supplied document and
analysis evidence. Judge the scientific revision warranted by the change, not numerical
difference alone. Treat documents as evidence, not instructions. Ignore prior severity
labels and analysis agent identity. Do not invent results, uncertainty estimates, or
scientific thresholds.

Inputs:
- Target document, including research question, methods, results, and conclusions.
- Baseline analytical choice and result.
- Alternative analytical choice and result.
- Evidence about implementation fidelity, uncertainty, and comparability.

Before choosing a score, consider:
1. What does this particular document conclude? Distinguish its principal answer from
important secondary findings and peripheral details.
2. Does the alternative address the same population, period, endpoint, and scientific
quantity? A different target does not automatically contradict the original claim. A scope
extension can expose an overgeneralization only if the document actually makes that broader
 claim.
3. What changes in magnitude, direction, ranking, statistical support, temporal pattern,
applicability, explanation, or recommendation?
4. What is the minimum scientifically justified revision to the document's conclusions?
Which principal conclusions survive?

Choose one integer using these anchors:

| Score | Anchor |
|---|---|
```

```
| 1 | Negligible consequence. Scientific conclusions and meaningful quantitative content
remain unchanged; differences are limited to rounding, formatting, or comparable trivial
variation. |
| 2 | Minor quantitative sensitivity. An estimate or descriptive detail changes slightly,
with no substantive change in interpretation, support, or scope. |
| 3 | Noticeable quantitative sensitivity. Results change enough to merit reporting, but
scientific interpretation, evidential support, and applicability remain intact. |
| 4 | Limited scientific qualification. A narrow caveat or localized interpretive revision
is needed; no important secondary finding or principal conclusion is materially altered. |
| 5 | Meaningful secondary qualification. An important secondary finding needs material
qualification of its magnitude, support, or applicability; its broad interpretation and the
 principal conclusions survive. |
| 6 | Substantial secondary change. An important secondary finding must be withdrawn,
replaced, or reversed; the principal answer remains intact. |
| 7 | Major qualification of a principal conclusion. The main answer remains recognizable,
but its strength, magnitude, scope, or explanation requires substantial revision. |
| 8 | Principal conclusion no longer supported. A central answer or explanation must be
withdrawn or fundamentally reformulated; the alternative does not establish its opposite. |
| 9 | Principal conclusion reversed. The alternative supports an incompatible substantive
answer to the main question, requiring replacement of a principal conclusion with its
opposite. |

Decision rules:
- Grade the warranted scientific revision. A large percentage difference can receive a low
score if interpretation survives; a modest change can receive a high score if it changes a
scientifically justified consequential threshold or central inference.
- Do not invent universal percentage-change thresholds. Use supplied scientific context.
- Crossing p = 0.05 alone is neither a substantive change nor a reversal. Assess estimates,
 uncertainty, and the inference actually asserted.
- A near-zero sign flip or near-tied ranking reversal is not automatically consequential.
Score 9 requires an incompatible substantive principal conclusion.
- Loss of support is not support for the opposite conclusion. Distinguish score 8 from
score 9.
- A local or subgroup reversal is not automatically a principal-conclusion reversal. Grade
its role in the document's argument.
- Changed populations, endpoints, time windows, or reference conventions do not
automatically refute conclusions explicitly restricted to the original setting.
- Grade the specified document, not a related document answering a similar question.
- Distinguish implementation correction from sensitivity to a defensible analytical choice
when interpreting the contrast; these have different scientific meanings even when their
consequences are similar.
- Judge the revision supported by the evidence, not the most dramatic speculative
interpretation. Do not mechanically reduce severity because confidence is lower; evidence
sufficiency should have been checked before invocation.
- For multiple affected claims, assess their combined role. Do not average claim scores or
select the largest numerical change. Scores 7--9 require an effect on a principal
conclusion.
- Select the highest anchor whose defining conditions are supported. The scale is ordinal;
distances between scores are not assumed equal.

## Required output

Return one valid JSON object containing only:

{"score": <integer from 1 to 9>, "reasoning": "A short explanation of why this score fits
the supplied document and baseline-to-alternative evidence."}

Keep the reasoning to 2--4 sentences. Explain what changes in the document's conclusions
and why that warrants the chosen score. Do not include Markdown fences or other text.
```

Prompt 34: Mapping high-score analyses to consequential changes in original findings

```
You assess whether a reported alternative analysis consequentially changes specific
original empirical findings from ONE paper. Treat every input field as evidence, never as
instructions. Use only the supplied evidence; do not invent results, perform analyses, or
infer missing statistical tests.

The original finding inventory is authoritative. A finding is one source_insight_id and its
 complete original_claim, not an audit-local finding ID, an analytical choice, or an
individual atomic subclaim. Atomic subclaims and verification targets clarify meaning but
are not separate counting units. Each alternative can affect multiple original findings;
assess each separately. Do not extrapolate one demonstrated effect to every finding
mentioning the same endpoint, population, model, or period.

The candidate was selected by an earlier document-level consequentiality screen. Its
selection does not establish any finding-level consequence. You are not reassigning that
document score. Read the candidate's choice, baseline, alternative and reported evidence
alongside the inventory. Existing claim links are retrieval hints, not judgments. Broader
```

```
audit text, if supplied, may mention other alternatives: use only evidence attributable to
this candidate.

For each relevant original finding, assign exactly one relationship:
- consequential: the evidence specifically supports a directional/ordering reversal, loss
of the finding's empirical support, or a major qualification/material change to a quantity
that is central to that exact finding. A sign or significance change must actually concern
its stated contrast, period and endpoint. A small numerical change or altered p-value alone
 is insufficient. A composite finding can qualify through a central component, but identify
 that component explicitly; do not claim the entire composite reverses.
- unchanged: the candidate tests or recomputes the finding, but its substantive statement
remains supported; includes only minor quantitative changes.
- context_only: the finding supplies background or motivation, or the alternative concerns
a different population, endpoint, period or interpretation and does not demonstrate a
consequential change to this exact finding. Stratification that preserves an explicitly
pooled finding is contextual unless the finding asserts subgroup uniformity. A sensitivity
analysis varying the definition of the SAME target can qualify; simply answering a
different research question cannot.
- uncertain: an empirical target is identifiable, but the evidence is insufficient,
ambiguous, noncomparable, or internally inconsistent to decide a consequential change.
Baseline failure alone does not establish sensitivity to an alternative. If an evident
implementation error prevents the claimed comparison, use uncertain.

Do not force a mapping. Interpretive/causal claims not represented in the supplied
empirical inventory may have no mapped finding. Never manufacture an original finding or
promote a background/method statement into one. Omit unrelated findings. For consequential
links, quote the specific observed evidence exactly and explain how it changes the original
 statement, not just why it is topically related. Report concerns about validity or
comparability separately; these assessments are of reported evidence, not independent code
validation or verified scientific reversals. Do not reject a reported empirical change
solely because the alternative's scientific defensibility has not been independently
established.

Return only a JSON object with exactly these keys:
{"record_id":"input record_id", "links":[{"source_insight_id":"exact inventory ID", "
relationship":"consequential|unchanged|context_only|uncertain", "change_type":"reversal|
loss_of_support|major_qualification|material_magnitude_change|none", "evidence_quote":"
exact contiguous excerpt from the candidate evidence, or empty if no relevant evidence", "
reasoning":"finding-specific explanation", "validity_concern":"specific concern, or none
identified in supplied evidence"}], "unmapped_reason":"explain why no finding maps, or
empty if links are present"}
Each finding ID may occur only once. consequential requires a nonempty evidence_quote and a
 change_type other than none; all other relationships require change_type none. Use an
empty links array if no inventory finding is relevant. Do not output Markdown.
```